Cardiac-preferred genetic alteration of transgenic rabbits

ABSTRACT

The methods and compositions of the present invention find use in altering cardiac-preferred expression in transgenic animals. The compositions of the invention include animal cells, transgenic animals, and transgenic rabbits. The transgenic animals of the invention exhibit altered cardiac preferred expression of a heterologous nucleotide sequence. The methods allow generation of transgenic animals with altered cardiac preferred expression of the heterologous nucleotide sequence. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiopathy. A transgenic animal of the invention finds use in identifying anti-cardiopathic compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U.S. Provisional Application No. 60/454,947, filed on Mar. 13, 2003, which is herein incorporated by reference in its entirety.

GOVERNMENT GRANT INFORMATION

[0002] This invention was made with Government support under NIH Grant Nos. 1ROHL56370 and PO1 HL53218-01. The United States Government has certain rights in this invention.

FIELD OF THE INVENTION

[0003] The present invention relates to the field of regulation of tissue-preferred gene expression.

BACKGROUND OF THE INVENTION

[0004] A variety of human diseases and conditions which are manifested by cardiac abnormalities or cardiac dysfunction can lead to heart failure. Heart failure is a physiological condition in which the heart fails to pump enough blood to meet the circulatory requirements of the body. The study of such diseases and conditions in genetically diverse humans is difficult and unpredictable. Therefore, there is a need for a model system which facilitates the study of the mechanisms and causes of cardiac diseases and conditions as well as the identification of potential therapeutic targets.

[0005] The development of transgenic animal technology has provided significant advances for obtaining more complete information about complex systems in vivo. By manipulating the expression of a gene or genes in vivo, it is possible to gain insight into the roles of such genes in a particular system or to study aspects of the system in a genetically controlled environment.

[0006] While successful transgene experiments have been performed in a number of large and small animal species, the mouse has been the animal of choice for cardiovascular studies. See, for example, U.S. Pat. No. 6,353,151, herein incorporated by reference. Cardiac preferred transgenesis has been used to establish structure-function relationships between the presence or absence of a particular protein (or its mutated form) and normal or abnormal function at the molecular, cellular, and physiological levels. However, there are significant differences between mouse models and human disease presentation, particularly with regard to familial hypertrophic cardiomyopathies (FHC). Mouse models of FHC exhibit depressed contractility, absence of cardiac sudden death, a relatively small increase in ventricular mass, and a gender bias not found in human presentations of FHC. Mice hearts beat ten times faster than human hearts. The models diverge at the molecular level also; the α-myosin heavy chain isoform predominates in the adult mouse ventricle while the β-myosin heavy chain isoform predominates in adult human ventricles.

[0007] Thus, development of a transgenic model system is desirable for use in studying heart disease and conditions. It is of importance to develop a transgenic, cardiac-preferred expression model in system closely related to the human heart at the molecular, biochemical, and physiological levels. It is of particular importance to develop a model transgenic system for use in studying familial hypertrophic cardiomyopathies.

SUMMARY OF THE INVENTION

[0008] Compositions and methods for cardiac-preferred expression of heterologous nucleotide sequences are provided. Compositions of the invention include animals, particularly transgenic rabbits, and animal cells. Animals, transgenic rabbits, and animal cells of the invention comprise an expression cassette comprising a promoter capable of initiating tissue-preferred transcription, particularly cardiac-preferred transcription, operably linked to a heterologous nucleotide sequence. In an embodiment the promoter is capable of initiating ventricle-preferred transcription. In an embodiment the promoter is capable of initiating atria-preferred transcription. In animals and transgenic rabbits of the invention, expression of the heterologous nucleotide sequence is altered, particularly in cardiac tissue. In an embodiment, expression of the heterologous nucleotide sequence is ventricle-preferred. In an embodiment, expression of the heterologous nucleotide sequence is atria-preferred. In an embodiment, the transgenic rabbit's genome comprises a promoter capable of initiating ventricle-preferred transcription operably linked to a heterologous nucleotide sequence encoding the rabbit α-myosin heavy chain polypeptide. Transgenic rabbits comprising a heterologous nucleotide sequence encoding the rabbit α-myosin heavy chain polypeptide operably linked to a promoter capable of initiating ventricle-preferred transcription exhibit altered myosin-isoform expression.

[0009] Methods for modulating expression of heterologous nucleotide sequences in animals are provided. The animal's susceptibility to various cardiopathies, including but not limited to, cardiomyopathies, may be altered by the methods of the invention. Cardiomyopathies include, but are not limited to, familial hypertrophic cardiomyopathy, dilated cardiomyopathies, peripartum cardiomyopathy, and restrictive cardiomyopathies. In an embodiment, the animal exhibits increased susceptibility to cardiopathy. In one embodiment, the animal exhibits decreased susceptibility to cardiopathy. Expression cassettes comprising a promoter with a nucleotide sequence capable of initiating tissue-preferred, particularly cardiac-tissue preferred, transcription in the animal are developed. The promoter is operably linked to a heterologous nucleotide sequence of interest. An expression cassette comprising a promoter capable of initiating cardiac-preferred expression operably linked to a heterologous nucleotide sequence of interest is used to generate a transgenic animal. The genome of the animal incorporates at least one expression cassette comprising the promoter and the heterologous nucleotide sequence. The heterologous nucleotide sequence is preferentially expressed in a cardiac tissue. Expression of the heterologous nucleotide sequence can be assessed by any method known to one skilled in the art. In an embodiment the heterologous nucleotide sequence encodes a myocardial component such as, but not limited to, α-myosin heavy chain, β-myosin heavy chain, essential myosin light chain-1, actin, catecholamine receptors, and glycogen synthase 3-β.

[0010] Methods for identifying anti-cardiopathic compounds are provided. In an embodiment at least two transgenic rabbits whose genomes comprise at least one stably incorporated expression cassette comprising a promoter capable of initiating cardiac-preferred transcription operably linked to a heterologous nucleotide sequence are provided. A compound of interest is administered to the first rabbit. The first and second rabbits are incubated for a period of time. A cardiopathic phenotype is monitored in both rabbits. Cardiopathic phenotypes include, but are not limited to, mortality, cardiac myocyte disarray, interstitial fibrosis, systolic dysfunction, diastolic dysfunction, left ventricular hypertrophy, cardiac mass abnormalities, right ventricular outflow tract obstruction, morphological changes, cellular degeneration, and hyper-contractility.

[0011] In an embodiment, the invention provides a transgenic rabbit comprising at least one expression cassette comprising a promoter operably linked to a heterologous nucleotide sequence, wherein the transgenic nucleotide sequence is set forth in SEQ ID NO:5. In an aspect of the invention, the transgenic rabbit exhibits altered myosin isoform expression in ventricle tissue.

[0012] The invention further provides kits comprising a transgenic animal, particularly a transgenic rabbit comprising an expression cassette comprising a promoter having a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2 or a fragment or variant thereof and a heterologous nucleotide sequence operably linked to the promoter.

[0013] In an embodiment, the invention provides a kit for performing a method of altering expression of a heterologous nucleotide sequence in a rabbit comprising a transgenic rabbit of the invention.

[0014] In an embodiment, the invention provides a kit for performing a method of altering expression of a heterologous nucleotide sequence in an animal comprising an expression cassette comprising a promoter, wherein said promoter comprises a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, or a fragment or variant thereof.

[0015] In another embodiment, the invention provides a kit for altering an animal's susceptibility to cardiopathy. Such a kit comprises a transgenic animal of the invention, particularly a transgenic rabbit of the invention. In an aspect of the invention, the kit further comprises a non-transgenic animal, particularly a non-transgenic rabbit.

[0016] In an embodiment, the invention provides a kit for identifying anti-cardiopathic compounds. Such a kit comprises a first and second transgenic rabbit of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017]FIG. 1 depicts cardiac preferred expression of the CAT reporter gene operably linked to the β-myosin heavy chain promoter (SEQ ID NO:2). Tissues were obtained from multiple animals in the F2 generations of four stable transgenic lines. Two, fourteen, twenty-four, and thirty-nine copies of the transgene are present in the genomes of transgenic lines 415 (white bars), 428L (right slash bars), 428M (left slash bars), and 428H (hatched bars), respectively. Panel A presents the results of CAT ELISAs performed on tissues obtained from the apex, left ventricle (LV free), septum, right ventricle (RV free), left atria, and right atria. Panel B presents the results of CAT ELISAs performed on diaphragm (Dia) and soleus (Sol) tissues. The diaphragm contains mixed fiber types while the soleus is a slow skeletal muscle. Panel C presents the results of CAT ELISAs performed on bicep muscle (Bic), tibialis muscle (Tibi), masseter muscle (Mass), tongue (Tong), stomach (Stom), small intestine (S. Inte), lung (Lun), liver (Liv), and spleen (Sple). CAT activity is presented in pg/μg protein.

[0018]FIG. 2, Panel A presents the results of RNA analysis of cardiac tissue from transgenic (TG) and nontransgenic (NTG) rabbits. Right atria (RA), left atria (LA), right ventricles (RV), and left ventricles (LV) were isolated from a control animal and a transgenic rabbit carrying the β-myosin heavy chain promoter (SEQ ID NO:2) operably linked to the α-myosin heavy chain coding sequence (SEQ ID NO:3). RNA was isolated from the tissues and dotted on to a membrane as described elsewhere herein. The dot blots were probed with radiolabeled oligonucleotides specific to either the α-myosin heavy chain gene (α) or the β-myosin heavy chain gene (β) as described elsewhere herein.

[0019]FIG. 2, Panel B presents the results of protein analysis of cardiac tissue from a control animal and a transgenic rabbit carrying the β-myosin heavy chain promoter (SEQ ID NO:2) operably linked to the α-myosin heavy chain coding sequence (SEQ ID NO:3). Lanes 1 and 2 contain samples from the right atria (RA) and left ventricle (LV) of the control rabbit. Lanes 3, 4, 5, and 6 contain total protein samples from the right atria (RA), left atria (LA), right ventricle (RV), and left ventricle (LV) of the transgenic rabbit. The proteins were resolved by electrophoreses on polyacrylamide gels and transferred to nylon membranes. The membranes were probed with α-myosin heavy chain specific antibodies to detect the α-myosin heavy chain polypeptide.

[0020]FIG. 3 presents the results of actin-activated ATPase experiments performed on cardiomyocytes obtained from transgenic ventricles, non-transgenic ventricles, and rabbit atria. The actin concentration is indicated in μmol on the x-axis. Inorganic phosphate (Pi) is indicated in nmol Pi produced per minute per mg of total protein on the y-axis. Data obtained from non-transgenic ventricles (primarily P-MHC) are indicated with solid diamonds. Data obtained from transgenic ventricles (α-MHC/β-MHC) are indicated with open squares. Data obtained from atria (α-MHC) are indicated with solid triangles.

[0021]FIG. 4 depicts an implanted device used to alter cardiac pace and data obtained from animals implanted with such a device. An implanted pacemaker device is shown in Panel A. Echocardiograms obtained from transgenic and non-transgenic rabbits are shown in Panel B and Panel C, respectively. Experimental details are described elsewhere herein.

[0022]FIG. 5 presents the shortening fractions of transgenic (white squares) and non-transgenic (solid diamonds) rabbits determined prior to implantation of a pacemaker (Pre-op) and prior to initiating the indicated paces. Shortening fractions were determined before pacing the animals to 300 beats per minute (Pre-300), 340 beats per minute (Pre-340), 380 beats per minute (Pre-380), and ten days after pacing the animals to 380 beats per minute (Final). Experimental details are described elsewhere herein.

[0023]FIG. 6 presents the heart rate corrected velocity of circumferential shortening (V_(CFC)) and left ventricular end-systolic meridional wall stress (WS, measured in g/cm²) of transgenic (hatched circles) and nontransgenic (left slash circles) rabbits after undergoing the pacing protocol described above. The large circles indicate the mean values for each group. The data are superimposed on numbers derived from healthy human subjects (empty circles); see Kimball et al. (1991) Am. J. Cardiol. 68:1383-1387.

DETAILED DESCRIPTION OF THE INVENTION

[0024] The present invention provides for cardiac-preferred expression of transgenes in animals. Compositions of the invention include transgenic rabbits comprising a promoter of the invention operably linked to a nucleotide sequence of interest. The invention provides methods for altering expression of a nucleotide sequence of interest in an animal. Expression of the nucleotide sequences of interest may alter a transgenic animal's susceptibilities to cardiopathies. Further, the invention provides methods for identifying anti-cardiopathic compounds.

[0025] The invention relates to compositions and methods drawn to the rabbit α-myosin heavy chain promoter (SEQ ID NO: 1), β-myosin heavy chain promoter (SEQ ID NO:2), the α-myosin heavy chain (SEQ ID NO:3), and methods of their use. An animal cell or animal of the invention is stably transformed with an expression cassette comprising the cardiac-preferred promoters set forth in SEQ ID NO: 1 or 2 operably linked to a heterologous nucleotide sequence. The promoter sequences are useful for expressing operably linked sequences in a tissue-preferred, preferably cardiac-tissue preferred expression pattern. In an embodiment the rabbit α-myosin heavy chain promoter (SEQ ID NO: 1) is an atria-preferred promoter. In an embodiment, the rabbit β-myosin heavy chain promoter (SEQ ID NO:2) is a ventricle-preferred promoter.

[0026] Transgenic embryos of the transgenic rabbits of the invention were deposited with the Patent Depository of the American Type Culture Collection (ATCC), Manassas, Va. on ______, ______ and assigned Patent Deposit No. ______. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112.

[0027] By “stably transformed” is intended that the nuclear genome of the animal cell or the nuclear genome of at least one cell of the animal has incorporated at least one copy of the transgene. A transgenic animal of the invention comprises at least one stably transformed cell comprising the nucleotide sequence of interest. In an embodiment, the genome of a germ-line cell of a transgenic animal comprises the nucleotide sequence of interest. The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An “isolated” or substantially “purified” nucleic acid molecule, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an “isolated” nucleic acid molecule is free of sequences (preferably polypeptide encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.

[0028] The promoters for the α-myosin heavy chain and β-myosin heavy chain genes may generally be isolated from the 5′ untranslated region flanking their respective transcription initiation sites. Methods for isolation of promoter regions are well known in the art. By “isolated” is intended that the promoter sequences have been determined and can be extracted by molecular techniques or synthesized by chemical means. In either instance, the promoter is removed from at least one of its flanking sequences in its native state.

[0029] Fragments and variants of the disclosed nucleotide sequences are also encompassed by the present invention. By “fragment” is intended a portion of the nucleotide sequence. Fragments of a nucleotide sequence may retain biological activity and drive expression, particularly tissue-preferred expression, more particularly cardiac-preferred expression, yet more particularly ventricle-preferred or atria-preferred expression. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not retain biological activity. Thus, fragments of a nucleotide sequence may range from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, up to about 5190 nucleotides for SEQ ID NO: 1; from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, up to about 6921 nucleotides for SEQ ID NO:2; from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, and up to about 5886 nucleotides for SEQ ID NO:3; from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 960, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000, 10100, 10200, 10300, 10400, 10500, 10600, 10700, 10800, 10900, 11000, 11100, 11200, 11300, 11400, 11500, 11600, 11700, 11800, 11900, 12000, 12100, 12200, 12300, 12400, 12500, 12600, 12700, 12800, and up to about 12,801 nucleotides for SEQ ID NO:5.

[0030] Thus a fragment of a nucleotide sequence for cardiac-preferred promoters may encode a biologically active portion of a cardiac tissue-preferred promoter, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a cardiac tissue preferred promoter can be prepared by isolating a portion of the promoter nucleotide sequence disclosed herein, and assessing the activity of the portion of the promoter. Nucleic acid molecules that are fragments of a cardiac-preferred promoter comprise 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, up to about 5190 nucleotides for SEQ ID NO:1; from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, up to about 6921 nucleotides for SEQ ID NO:2; from at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, or up to 6921 for SEQ ID NO:5.

[0031] By “variants” is intended substantially similar sequences. For nucleotide sequences, naturally occurring variants can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reactions (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated for example, by using site-directed mutagenesis. Generally, variants of a particular nucleotide sequence of the invention will have at least 85%, generally at least 90%, 91%, 92%, 93%, 94%, preferably about 95%, 96%, 97%, and more preferably 98%, 99%, or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Pat. No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Co., New York) and the references cited therein.

[0032] Variant nucleotide sequences also encompass sequences derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different promoter sequences including the promoter sequences disclosed herein, can be manipulated to create a new promoter sequence possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994) Proc. Natl. Acad. Sci.91:10747-10751; Stemmer (1994) Nature 370:389-391; Crameri et al. (1997) Nature Biotech. 15:436-438; Moore et al. (1997) J. Mol. Biol. 272:336-347; Zhang et al. (1997) Proc. Natl. Acad. Sci. 94:4504-4509; Crameri et al. (1998) Nature 391:288-291; Miyazaki (2002) Nucleic Acids Research 30:E139-9; Song et al. (2002) Appl. Environ. Microbiol. 68:6146-51; Hayes et al. (2002) Proc. Natl Acad Sci. 99:15926-31; Coco et al. (2001) Nature Biotechnol. 19:354-9; Kikuchi et al. (2000) Gene 243:133-7; and U.S. Pat. Nos. 5,606,793 and 5,837,458.

[0033] The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) “reference sequence”, (b) “comparison window”, (c) “sequence identity”, (d) “percentage of sequence identity”, and (e) “substantial identity”.

[0034] (a) As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence or the complete cDNA or gene sequence.

[0035] (b) As used herein “comparison window” makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e. gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.

[0036] Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent sequence identity between any two sequences can be accomplished using a mathematical algorithm. Preferred, non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (1988) CABIOS 4:11-17; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453; the search-for-similarity-method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

[0037] Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. For purposes of the present invention, comparison of nucleotide or protein sequences for determination of percent sequence identity to the sequences disclosed herein is preferably made using the GCG program GAP (Version 10.00 or later) with its default parameters or any equivalent program. By “equivalent program” is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program.

[0038] Sequence comparison programs include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, Calif.); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis., USA). Alignments using these programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins et al. (1988) Gene 73:237-244 (1988); Higgins et al. (1989) CABIOS 5:151-153; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) CABIOS 8:155-65; and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331. The ALIGN program is based on the algorithm of Myers and Miller (1988) supra. A PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences. The BLAST programs of Altschul et al. (1990) J. Mol. Biol. 215:403 are based on the algorithm of Karlin and Altschul (1990) supra. BLAST nucleotide searches can be performed with the BLASTN program, score=100, wordlength=12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a protein of the invention. BLAST protein searches can be performed with the BLASTX program, score=50, wordlength=3, to obtain amino acid sequences homologous to a protein or polypeptide of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for proteins) can be used. See http://www.ncbi.nlm.nih.gov. Alignment may also be performed manually by inspection.

[0039] (c) As used herein, “sequence identity” or “identity” in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity”. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of I and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).

[0040] (d) As used herein, “percentage of sequence identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

[0041] (e)(i) The term “substantial identity” of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90%, and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

[0042] Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1° C. to about 20° C. lower than the T_(m), depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

[0043] (e)(ii) The term “substantial identity” in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are “substantially similar” share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.

[0044] The nucleotide sequences disclosed herein can be used to isolate corresponding sequences from other organisms, particularly other mammals. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire sequences set forth herein or to fragments thereof are encompassed by the present invention. Comparable promoter regions from other organisms, including other mammals, may be obtained by utilization of the coding or promoter sequences set forth herein.

[0045] In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any animal of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.). See also Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like.

[0046] In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as ³²P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the promoter sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).

[0047] For example, an entire promoter sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding promoter sequences. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among cardiac-preferred promoter sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding promoter sequences from a chosen animal by PCR. This technique may be used to isolate additional promoter sequences from a desired animal or as a diagnostic assay to determine the presence of the promoter sequences in an animal or animal cell.

[0048] Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).

[0049] Hybridization of such sequences may be carried out under stringent conditions. By “stringent conditions” or “stringent hybridization conditions” is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.

[0050] Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° C., and a wash in 1×to 2×SSC (20×SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37° C., and a wash in 0.5× to 1×SSC at 55 to 60° C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.1×SSC at 60 to 65° C. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours.

[0051] Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_(m) can be approximated from the equation of Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284: T_(m)=81.5° C.+16.6 (log M)+0.41 (% GC)−0.61 (% form)−500/L; where M is the molarity of monovalent cations, % GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_(m) is reduced by about 1° C. for each 1% of mismatching; thus, T_(m), hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with approximately 90% identity are sought, the T_(m) can be decreased 110° C. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (T_(m)) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4° C. lower than the thermal melting point (T_(m)); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10° C. lower than the thermal melting point (T_(m)); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20° C. lower than the thermal melting point (T_(m)). Using the equation, hybridization and wash compositions, and desired T_(m), those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_(m) of less than 45° C. (aqueous solution) or 32° C. (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, N.Y.); and Ausubel et al., eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.). Thus, isolated sequences that have promoter activity and which hybridize under stringent conditions to the cardiac-preferred promoter sequences disclosed herein, or to fragments thereof, are encompassed by the present invention. Such sequences will be at least 85%, 90%, 95% to 98% homologous or more with the disclosed sequences. That is, the sequence identity of sequences may range, sharing at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity.

[0052] Cardiac preferred promoters disclosed in the invention may be isolated from any animal, including but not limited to, rabbit, mouse, monkey, chimpanzee, dog, pig, goat, sheep, cat, and cow. It is recognized that any gene of interest can be operably linked to a promoter of the invention and expressed in cardiac tissue. By “cardiac tissue” is intended any tissue obtained from the heart, including but not limited to, tissues developmentally related to the heart. By “ventricle tissue” is intended any tissue obtained from any portion of either ventricle of the heart. By “atria tissue” is intended any tissue obtained from any portion of either atria of the heart.

[0053] General categories of genes of interest for the purposes of the present invention include for example, those genes involved in information, such as Zinc fingers, those involved in communication, such as kinases, and those involved in housekeeping, such as heat shock proteins. For example, genes of interest include but are not limited to, potassium channel genes, nitric oxide synthases, glycoprotein receptors, class 1 HLA, class 2 HLA, cathepsin B, cysteine aminopeptidases, acid gelatinases, trypsin-like endopeptidases, chymotrypsin-like endopeptidases, neutral gelatinases, angiotensin type-II receptors, myocardial sarcoplasmic reticulum Ca²⁺-ATPase, troponin T, troponin I, α-tropomyosin, TGF-β1, IGF-I, IGF-II, PDGF-B, prorenin, rennin, myosin binding protein C, ion channel genes, retinoic acid receptors, α-myosin heavy chains, β-myosin heavy chains, essential myosin light chains, actins, and sarcomere components.

[0054] It is recognized that the genes of interest vary for an atria-preferred promoter, such as the promoter set forth in SEQ ID NO:1, versus a ventricle-preferred promoter, such as the promoter set forth in SEQ ID NO:2.

[0055] The heterologous nucleotide sequence expressed by the promoters of the invention may be used for varying the phenotype of the heart. Various phenotypes of interest in cardiac tissue include, but are not limited to, hypertrophy; morphology, such as interventricular septal thickness; left ventricular-end systolic or end-diastolic dimensions; papillary muscle dimension; left-ventricular outflow tract obstruction; sarcomere structure, particularly alterations resulting in familial hypertrophic cardiomyopathy; alteration of myosin isoform expression, particularly resulting in altered susceptibility to cardiopathies; myofibril function; cardiopathic susceptibility; responsiveness to anti-cardiopathic compounds; receptor expression; heart rate; ventricular systolic pressure, ventricular diastolic pressure; aortic systolic pressure; aortic diastolic pressure; contractility; interstitial fibrosis; cardiomyocyte disarray; Ca²⁺ sensitivity; catecholine sensitivity; α-adrenergic sensitivity; beta-adrenergic sensitivity; angiotensin-converting enzyme inhibitor sensitivity; amiodarone sensitivity; lidocaine sensitivity; glycoprotein receptor antagonist sensitivity; anabolic steroid sensitivity; and the like.

[0056] These results can be achieved by providing expression of heterologous products or increased expression of endogenous products in cardiac tissue. Alternatively, the results can be achieved by providing for a reduction of expression of one or more endogenous products, particularly enzymes and cofactors in the cardiac tissue. These changes result in a change in phenotype of the transgenic animal. For example, the promoter sequences of the invention can be used to preferentially express the α-myosin heavy chain isoform in the ventricles and alter the myosin isoform expression pattern. Alternatively, the promoter sequences of the invention can be used to produce antisense mRNA complementary to the coding sequence of a cardiac protein, inhibit production of the protein, and alter expression of the heterologous nucleotide sequence. Alternatively, the promoter sequences of the invention can be used to produce small interfering RNAs.

[0057] Products of the heterologous nucleotide sequence include structural proteins, enzymes, cofactors, hormones, signaling proteins, and the like.

[0058] As noted, the heterologous nucleotide sequence operably linked to one of the promoters disclosed herein may be an antisense sequence for a targeted gene. Thus, with these promoters, antisense constructions complementary to at least a portion of the messenger RNA (mRNA) for a targeted sequence sequences can be constructed. Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications of the antisense sequences may be made as long as the sequences hybridize to and interfere with expression of the corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%, more preferably 85% sequence identity to the corresponding antisensed sequences may be used. Furthermore, portions of the antisense nucleotides may be used to disrupt the expression of the target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used. Thus, the promoter sequences disclosed herein may be operably linked to antisense DNA sequences to reduce or inhibit expression of a native protein in cardiac tissue.

[0059] By “promoter” or “transcriptional initiation region” is intended a regulatory region of DNA usually comprising a TATA box capable of directing RNA polymerase II to initiate RNA synthesis at the appropriate transcription initiation site for a particular coding sequence. A promoter may additionally comprise other recognition sequences generally positioned upstream or 5′ to the TATA box, referred to as upstream promoter elements, which influence the transcription initiation rate. It is recognized that having identified the nucleotide sequences for the promoter regions disclosed herein, it is within the state of the art to isolate and identify further regulatory elements in the 5′ untranslated region, typically downstream from the particular promoter regions identified herein. Thus, the promoter regions disclosed herein are generally further defined by comprising upstream regulatory elements such as those responsible for tissue and temporal expression of the coding sequence, enhancers and the like. Such elements are typically linked via a 5′ untranslated region, which may further modulate gene expression, to a coding region of interest. In the same manner, the promoter elements which enable expression in the desired tissue such as cardiac-tissue can be identified, isolated, and used with other core promoters to confirm cardiac-preferred expression. For genes in which the 5′ untranslated region does not affect cell specificity, alternative sources of 5′ untranslated leaders may be used in conjunction with these promoter elements.

[0060] The regulatory sequences of the present invention, when operably linked to a heterologous nucleotide sequence of interest and inserted into an expression vector, enable cardiac-preferred expression of the heterologous nucleotide sequence in the cardiac tissue of an animal stably transformed with this expression vector. By “cardiac-preferred” is intended that expression of the heterologous sequence is most abundant in cardiac tissue, while some expression may occur in other tissue types, particularly in tissues developmentally related to cardiac tissue. Cardiac-preferred expression of a heterologous nucleotide sequence of interest occurs at levels at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% greater than expression of the nucleotide sequence of interest in non-cardiac tissue. By “ventricle-preferred” is intended that expression of the heterologous sequence is most abundant in ventricle tissues, while some expression may occur in other tissue types. Ventricle-preferred expression of a nucleotide sequence of interest occurs at levels at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% greater than expression of the heterologous nucleotide sequence of interest in non-ventricular tissue. In an embodiment, ventricle-preferred expression of a heterologous nucleotide sequence natively expressed in atrial tissue may be desired. For example, ventricular expression of the atrial myosin heavy chain isoform may be desired. Expression of a heterologous nucleotide sequence from a ventricle-preferred promoter may not impact atrial expression of the nucleotide sequence operably linked to its native promoter. By “atria-preferred” is intended that expression of the heterologous sequence is most abundant in atrial tissues, while some expression may occur in other tissue types. Atria-preferred expression of a heterologous nucleotide sequence occurs at levels at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% greater than expression of the heterologous nucleotide sequence in non-atrial tissue.

[0061] By “heterologous nucleotide sequence” is intended a sequence that is not naturally occurring with the promoter sequence. While this nucleotide sequence is heterologous to the promoter sequence, it may be homologous, or native, or heterologous, or foreign, to the animal host.

[0062] It is recognized that the promoters may be used with their native coding sequences to increase or decrease expression resulting in a change in phenotype in the cardiac tissue of the transformed animal.

[0063] The isolated promoter sequences of the present invention can be modified to provide for a range of expression levels of the heterologous nucleotide sequence. Thus, less than the entire promoter regions may be utilized and the ability to drive cardiac-preferred expression retained. However, it is recognized that expression levels of mRNA may be altered and usually decreased with deletions of portions of the promoter sequences. Generally, at least about 20 nucleotides of an isolated promoter sequence will be used to drive expression of a nucleotide sequence.

[0064] It is recognized that to increase transcription levels or to alter tissue specificity, enhancers and/or tissue-preference elements may be utilized in combination with the promoter regions of the invention. For example, quantitative or tissue specificity upstream elements from other cardiac-preferred promoters may be combined with the promoter regions of the invention to augment cardiac-preferred transcription. Such elements have been characterized, for example, the murine TIMP-4 promoter (Rahkonen, et al. (2002) Biochim Biophys Acta 1577:45-52), A and B-type natriuretic peptide promoters (Grepin et al. (1994) Mol. Cell Biol. 14:3115-29), human cardiac troponin I promoter (Dellow, et al. (2001) Cardiovasc. Res.50:3-6), mouse S100A1 promoter (Kiewitz, et al. (2000) Biochim Biophys Acta 1498:207-19), salmon cardiac peptide promoter (Majalahti-Palviainen, et al (2000) Endocrinology 141:731-740), GATA response element (Charron et al. (1999) Molecular & Cellular Biology 19:4355-4365) and the like, herein incorporated by reference.

[0065] Other enhancers are known in the art that would alter the tissue specificity by driving expression in other tissues in addition to cardiac tissue, such as in skeletal tissue, CNS tissue, pulmonary tissue, salivary tissue, lacrimal tissue, and vascular tissue, among others. These include, for example, upstream elements from the promoter of the aquaporin-5 promoter (Borok, et al. (2000) J. Biol. Chem. 275:26507-14, herein incorporated by reference) which would give pulmonary and salivary-preferred expression in addition to cardiac-preferred expression. Another example includes upstream elements from the human alpha-skeletal actin promoter, which would give expression in skeletal muscle, in addition to cardiac-preferred expression.

[0066] Modifications of the isolated promoter sequences of the present invention can provide for a range of expression of the heterologous nucleotide sequence. Thus, they may be modified to be weak promoters or strong promoters. Generally, by “weak promoter” is intended a promoter that drives expression of a coding sequence at a low level. By “low level” is intended at levels of about {fraction (1/10,000)} transcripts to about {fraction (1/100,000)} transcripts to about {fraction (1/500,000)} transcripts; conversely, a strong promoter drives expression of a coding sequence at a high level, or at about {fraction (1/10)} transcripts to about {fraction (1/100)} transcripts to about {fraction (1/1000)} transcripts.

[0067] The nucleotide sequences for the cardiac-preferred promoter disclosed in the present invention, as well as variants and fragments thereof, are useful in the genetic manipulation of any animal when operably linked with a heterologous nucleotide sequence whose expression is to be controlled to achieve a desired phenotypic response. By “operably linked” is intended the transcription of the heterologous nucleotide sequence is under the influence of the promoter sequence. In this manner, the nucleotide sequences for the promoters of the invention may be provided in expression cassettes along with heterologous nucleotide sequences for expression in the animal of interest, more particularly in the heart of the animal.

[0068] Such expression cassettes will comprise a transcriptional initiation region comprising one of the promoter nucleotide sequences of the present invention, or variants or fragments thereof, operably linked to the heterologous nucleotide sequence whose expression is to be controlled by the cardiac-preferred promoters disclosed herein. Such an expression cassette is provided with at least one restriction site for insertion of the nucleotide sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

[0069] The expression cassette will include in the 5′-to-3′ direction of transcription, a transcriptional and translational initiation region, and a heterologous nucleotide sequence of interest. In addition to containing sites for transcription initiation and control, expression cassettes can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).

[0070] The expression cassette comprising the promoter sequence of the present invention operably linked to a heterologous nucleotide sequence may also contain at least one additional nucleotide sequence for a gene to be co-transformed into the organism. Alternatively, the additional sequence(s) can be provided on another expression cassette.

[0071] The regulatory sequences to which the polynucleotides described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

[0072] In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

[0073] Where appropriate, the heterologous nucleotide sequence whose expression is to be under the control of the promoter sequence of the present invention and any additional nucleotide sequence(s) may be optimized for increased expression in the transformed animal. That is, these nucleotide sequences can be synthesized using species preferred codons for improved expression, such as rabbit-preferred codons for improved expression in rabbits or mouse-preferred codons in mice. Methods are available in the art for synthesizing species-preferred nucleotide sequences. See, for example, Wada et al. (1992) Nucleic Acids Res. 20 (Suppl.), 2111-2118; Butkus et al. (1998) Clin Exp Pharmacol Physiol Suppl. 25:S28-33; and Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., herein incorporated by reference.

[0074] Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the heterologous nucleotide sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

[0075] The expression cassettes may additionally contain 5′ leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5′ noncoding region) (Elroy-Stein et al. (1989) Proc. Nat. Acad. Sci. USA 86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Allison et al. (1986)); MDMV leader (Maize Dwarf Mosaic Virus) (Virology 154:9-20); and human immunoglobulin heavy-chain binding protein (BiP) (Macejak et al. (1991) Nature 353:90-94). Other methods known to enhance translation and/or mRNA stability can also be utilized, for example, introns, and the like.

[0076] In those instances where it is desirable to have the expressed product of the heterologous nucleotide sequence directed to a particular organelle, particularly the mitochondria, the nucleus, the endoplasmic reticulum, the Golgi apparatus; or secreted at the cell's surface or extracellularly; the expression cassette may further comprise a coding sequence for a transit peptide. Such transit peptides are well known in the art and include, but are not limited to, the transit peptide for the acyl carrier protein, the small subunit of RUBISCO, and the like.

[0077] In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose; in vitro mutagenesis; primer repair; restriction; annealing; substitutions, for example, transitions and transversions; or any combination thereof may be involved.

[0078] Reporter genes or selectable marker genes may be included in the expression cassettes. Examples of suitable reporter genes known in the art can be found in, for example, Ausubel et al. (2002) Current Protocols in Molecular Biology. John Wiley & Sons, New York, N.Y., herein incorporated by reference.

[0079] Selectable marker genes for selection of transformed cells or tissues can include genes that confer antibiotic resistance. Examples of suitable selectable marker genes include, but are not limited to, genes encoding resistance to chloramphenicol (Herrera Estrella et al. (1983) EMBO J. 2:987-992); methotrexate (Herrera Estrella et al. (1983) Nature 303:209-213; Meijer et al. (1991) Plant Mol. Biol. 16:807-820); hygromycin (Waldron et al. (1985) Plant Mol. Biol. 5:103-108; Zhijian et al. (1995) Plant Science 108:219-227); streptomycin (Jones et al. (1987) Mol. Gen. Genet. 210:86-91); spectinomycin (Bretagne-Sagnard et al. (1996) Transgenic Res. 5:131-137); bleomycin (Hille et al. (1990) Plant Mol. Biol. 7:171-176); sulfonamide (Guerineau et al. (1990) Plant Mol. Biol. 15:127-136); puromycin (Abbate et al (2001) Biotechniques 31:336-40; cytosine arabinoside (Eliopoulos et al. (2002) Gene Ther. 9:452-462); 6-thioguanine (Tucker et al. (1997) Nucleic Acid Research 25:3745-46).

[0080] Other genes that could serve utility in the recovery of transgenic events but might not be required in the final product would include, but are not limited to, examples such as GUS (b-glucoronidase; Jefferson (1987) Plant Mol. Biol. Rep. 5:387); GFP (green fluorescence protein; Wang et al. (2001) Anim Biotechnol 12:101-110; Chalfie et al. (1994) Science 263:802), BFP (blue fluorescence protein; Yang et al. (1998) J. Biol. Chem. 273:8212-6), CAT; and luciferase (Riggs et al. (1987) Nucleic Acid Res. 15 (19):81 15; Luchrsen et al. (1992) Methods Enzymol. 216: 397-414).

[0081] Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included.

[0082] In one embodiment, the animal cell can be a fertilized oocyte or embryonic stem cell that can be used to produce a transgenic animal comprising at least one stably transformed expression cassette comprising the heterologous nucleotide sequence. Alternatively, the host cell can be a stem cell or other early tissue precursor that gives rise to a specific subset of cells and can be used to produce transgenic tissues in an animal. See also Thomas et al., (1987) Cell 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has recombined with the genome are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the recombined DNA by germ line transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos. WO 90/11354; WO 91/01140; and WO 93/04169.

[0083] The genetically engineered host cells can be used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rabbit, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a cardiac component and identifying and evaluating modulators of cardiopathic phenotypes.

[0084] Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; 4,873,191; and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

[0085] Similar methods are used for production of other transgenic animals. A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein. Methods for providing transgenic rabbits are described in Marian et al. (1999) J. Clin. Invest. 104:1683-1692 and James et al. (2000) Circulation 101:1715-1721, herein incorporated by reference in their entirety.

[0086] Other examples of transgenic animals include non-human primates, sheep, dogs, pigs, cows, goats, mice, and rats.

[0087] In another embodiment, transgenic non-human animals can be produced which contain selected systems, which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. (1992) PNAS 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0088] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_(o) phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to a pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

[0089] In an embodiment, the invention provides a method of altering expression of a heterologous nucleotide sequence in an animal, particularly of altering cardiac-preferred expression of the heterologous nucleotide sequence. In the method the heterologous nucleotide sequence is operably linked to a cardiac preferred promoter such as the nucleotide sequence presented in SEQ ID NO:1 or SEQ ID NO:2. An expression cassette comprising the cardiac preferred promoter operably linked to the heterologous nucleotide sequence is used to transform an animal. Animal transformation methods are known in the art and reviewed elsewhere herein. The method yields a stably transformed transgenic animal exhibiting altered expression of a heterologous nucleotide sequence.

[0090] By “altered cardiac-preferred expression” is intended that the expression of the heterologous nucleotide sequence in a transgenic cell or cardiac tissue of a transgenic animal of the invention differs from expression levels in a non-transgenic cell or cardiac tissue of a non-transgenic animal by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. The difference may be an increase or decrease in expression levels.

[0091] Methods of determining expression levels are known in the art and include, but are not limited to, qualitative Western blot analysis, immunoprecipitation, radiological assays, polypeptide purification, spectrophotometric analysis, Coomassie staining of acrylamide gels, ELISAs, RT-PCR, 2-D gel electrophoresis, microarray analysis, in situ hybridization, chemiluminescence, silver staining, enzymatic assays, ponceau S staining, multiplex RT-PCR, immunohistochemical assays, radioimmunoassay, colorimetric analysis, immunoradiometric assays, Northern blotting, fluorometric assays and SAGE. See, for example, Ausubel et al, eds. (2002) Current Protocols in Molecular Biology, Wiley-Interscience, New York, N.Y. and Coligan et al (2002) Current Protocols in Protein Science, Wiley-Interscience, New York, N.Y., herein incorporated by reference. Analysis of myosin isoform expression is described elsewhere herein.

[0092] Transgenic animals that exhibit altered cardiac preferred expression of the heterologous nucleotide sequence are useful to conduct assays that identify compounds that affect cardiac function. The altered cardiac-preferred expression of the heterologous nucleotide sequence may result in altered susceptibility to a cardiopathy.

[0093] A “cardiopathy” is any disorder or condition involving the heart or cardiac tissue. Disorders involving the heart, include but are not limited to, heart failure, including but not limited to, cardiac hypertrophy, left-sided heart failure, and right-sided heart failure; ischemic heart disease, including but not limited to angina pectoris, myocardial infarction, chronic ischemic heart disease, and sudden cardiac death; hypertensive heart disease, including but not limited to, systemic (left-sided) hypertensive heart disease and pulmonary (right-sided) hypertensive heart disease; valvular heart disease, including but not limited to, valvular degeneration caused by calcification, such as calcific aortic stenosis, calcification of a congenitally bicuspid aortic valve, and mitral annular calcification, and myxomatous degeneration of the mitral valve (mitral valve prolapse), rheumatic fever and rheumatic heart disease, infective endocarditis, and noninfected vegetations, such as nonbacterial thrombotic endocarditis and endocarditis of systemic lupus erythematosus (Libman-Sacks disease), carcinoid heart disease, and complications of artificial valves; myocardial disease, including but not limited to dilated cardiomyopathy; hypertrophic cardiomyopathy, restrictive cardiomyopathy, and myocarditis; pericardial disease, including but not limited to, pericardial effusion and hemopericardium and pericarditis, including acute pericarditis and healed pericarditis, and rheumatoid heart disease; Brock's disease, neoplastic heart disease, including but not limited to, primary cardiac tumors, such as myxoma, lipoma, papillary fibroelastoma, rhabdomyoma, and sarcoma, and cardiac effects of noncardiac neoplasms, congenital heart disease, including but not limited to, left-to-right shunts—late cyanosis, such as atrial septal defect, ventricular septal defect, patent ductus arteriosus, and atrioventricular septal defect, right-to-left shunts—early cyanosis, such as tetralogy of fallot, transposition of great arteries, truncus arteriosus, tricuspid atresia, and total anomalous pulmonary venous connection, obstructive congenital anomalies, such as coarctation of aorta, pulmonary stenosis and atresia, and aortic stenosis and atresia; disorders involving cardiac transplantation; myocardial stunning; arterial hypertension; peripartum cardiomyopathy; alcoholic cardiomyopathy; supraventricular tachycardia, bradycardia; atrial flutter; hydrops fetalis; extrasystolic arrhythmia; fetal cardiac arrhythmia; endocarditis; atrial fibrillation; idiopathic dilated cardiomyopathy; Chagas' heart disease; long QT syndrome; and Brugada syndrome.

[0094] A “cardiomyopathy” is any disorder or condition involving cardiac muscle tissue. Disorders involving cardiac muscle tissue include, but are not limited to, myocardial disease, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, myocardial stunning, and myocarditis; rheumatic fever; rhabdomyoma; sarcoma; congenital heart disease, including but not limited to, left-to-right shunts—late cyanosis, such as atrial septal defect, ventricular septal defect, patent ductus arteriosus, and atrioventricular septal defect, right-to-left shunts—early cyanosis, such as tetralogy of fallot, transposition of great arteries, truncus arteriosus, tricuspid atresia, and total anomalous pulmonary venous connection, obstructive congenital anomalies, such as coarctation of aorta, pulmonary stenosis and atresia, and aortic stenosis and atresia; disorders involving cardiac transplantation; arterial hypertension; peripartum cardiomyopathy; alcoholic cardiomyopathy; supraventricular tachycardia; bradycardia; atrial flutter; hydrops fetalis; extrasystolic arrhythmia; fetal cardiac arrhythmia; endocarditis; atrial fibrillation; idiopathic dilated cardiomyopathy; Chagas' heart disease; long QT syndrome; and Brugada syndrome.

[0095] By “altered susceptibility” is intended that a transgenic animal of the invention differs from a non-transgenic animal in the extent to which the transgenic animal of the invention exhibits a cardiopathic phenotype. The cardiopathic phenotype may present during any stage of development including, but not limited to, embryonically, post-natally, in the adult, and as the animal nears end of lifespan. In an embodiment, the cardiopathic phenotype may be induced by external stimuli such as, but not limited to, diet, exercise, chemical treatment, or surgical procedure. In an embodiment, a transgenic rabbit of the invention exhibits decreased susceptibility to cardiopathy. In an embodiment, a transgenic rabbit of the invention exhibits increased susceptibility to cardiopathy.

[0096] Cardiopathic phenotypes include, but are not limited to, hypertrophy; morphology, such as interventricular septal hypertrophy; left ventricular-end systolic dP/dt_(max) or end-diastolic dimension(r); papillary muscle dimension; left-ventricular outflow tract obstruction; midventricular hypertrophy; apical hypertrophy; asymmetrical hypertrophy; concentric enlarged ventricular mass; eccentric enlarged ventricular mass; sarcomere structure; myofibril function; receptor expression; heart rate; ventricular systolic pressure; ventricular diastolic pressure; aortic systolic pressure; aortic diastolic pressure; contractility; interstitial fibrosis; cardiomyocyte disarray; Ca²⁺ sensitivity; Ca²⁺ release; Ca²⁺ uptake; catecholine sensitivity; α-adrenergic sensitivity; beta-adrenergic sensitivity; dobutamine sensitivity; thyroxine sensitivity; angiotensin-converting enzyme inhibitor sensitivity; amiodarone sensitivity; lidocaine sensitivity; glycoprotein receptor antagonist sensitivity; anabolic steroid sensitivity; carnitine transport irregularities; left ventricular dilation, reduced left ventricular ejection fraction; left atrial dilatation; diuretic sensitivity; volemia; ischemia; leukocyte flow properties; the polymorphonuclear leukocyte (PMN) membrane fluidity; PMN cytosolic Ca²⁺ content; high interventricular septal defects, rosette inhibition effect; contractile force transmission; myocardial fiber disarray; increased chamber stiffness; impaired relaxation; small-vessel disease; dyspnea; angina; presyncope; tachycardia; syncope; and the like. See, for example, Braunwald et al. (2002) Circulation 106:1312-1316 and Wigle et al. (1995) Circulation 92:1680-1692, hereby incorporated by reference in their entirety.

[0097] Methods for measuring cardiopathic phenotypes are known in the art and include, but are not limited to, echocardiography, transesophageal echocardiography, exercise tests, urine/catecholamine analysis, EIAs, light microscopy, heart catheterization, dynamic electrocardiography, MRI, multiplex RT-PCR, positron emission tomography, angiography, magnetic resonance spin echo, short-axis MRI scanning, Doppler velocity recordings, Doppler color flow imaging, stress thallium studies, cardiac ultrasound, chest X-ray, oxygen consumption test, electrophysiological studies, auscultation, scanning EM, gravimetric analysis, Holter monitoring, hematoxylin and eosin staining, trichrome staining, 2-D echocardiography, cardiotocography, baseline M-mode echocardiography, and myocardial lactate production assays. See, for example, Braunwald et al. (2002) Circulation 106:1312-1316; Sohal et al. (2001) Circulation Res. 89:20-25; Nagueh et al. (2000) Circulation 102:1346-1350; and Wigle et al. (1995) Circulation 92:1680-1692, hereby incorporated by reference in their entirety.

[0098] In an embodiment, a transgenic animal of the invention may be used to identify anti-cardiopathic compounds. An “anticardiopathic” compound modulates a cardiopathic phenotype. Modulation may be an increase or decrease in a cardiopathic phenotype. An anticardiopathic compound will modulate a cardiopathic phenotype by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. Methods for assaying cardiopathic phenotypes are described elsewhere herein. Any method of assaying a cardiopathic phenotype known in the art may be used to monitor the effects of the compound of interest on a transgenic animal of the invention.

[0099] To identify anti-cardiopathic compounds, multiple transgenic animals of the invention, e.g. at least a first and second transgenic animal, are provided. The terms “first,” “experimental,” or “test” transgenic animal refer to a transgenic animal to which a compound of interest is administered. The terms “second” or “control” transgenic animal refer to a transgenic animal to which a placebo is administered. In an embodiment, the first and second transgenic animals are clonal, age-matched, gender-matched, and subject to similar environmental conditions. In an embodiment, more than one animal may be a first transgenic animal. In an embodiment more than one animal may be a second transgenic animal.

[0100] After administration of either the compound of interest or the placebo, the first and second transgenic animals are incubated for a period of time. The period of time will have a predetermined duration appropriate to analysis of the cardiopathic phenotype. Such durations include, but are not limited to, 30 seconds; 1, 5, 10, 30, or 60 minutes; 8, 12, 24, 36, or 48 hours;3, 4, 5, 6, or 7 days; 2, 3, or 4 weeks; 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months; up to 3 years. Monitoring of a cardiopathic phenotype may occur continuously; at a single interval; or at multiple intervals, such as, but not limited to, hourly, daily, weekly, and monthly. Any method of assaying a cardiopathic phenotype known in the art may be used to monitor the effects of the compound of interest on a transgenic animal of the invention.

[0101] The term “administer” is used in its broadest sense and includes any method of introducing a compound into a transgenic animal of the present invention. This includes producing polypeptides or polynucleotides in vivo as by transcription or translation in vivo of polynucleotides that have been exogenously introduced into a subject. Thus, polypeptides or nucleic acids produced in the subject from the exogenous compositions are encompassed in the term “administer.”

[0102] A “compound” comprises, but is not limited to, nucleic acid molecules, peptides, peptidomimetics, lipids, antibodies, receptor inhibitors, ligands, sterols, steroids, hormones, kinases, kinase inhibitors, agonists, antagonists, ion-channel modulators, diuretics, enzymes, enzyme inhibitors, carbohydrates, deaminases, deaminase inhibitors, G-proteins, G-protein receptor inhibitors, ACE inhibitors, hormone receptor modulators, alcohols, reverse transcriptase inhibitors, neurotransmitter inhibitors, angiotensin converting enzyme inhibitors, digitalis, neurotransmitter receptor modulators, negative inotropic agents, β-blockers, Ca²⁺ antagonists, disopyramide, anti-arrhythmia agents, flecainide, and vasodilators. A compound may additionally comprise a pharmaceutically acceptable carrier.

[0103] As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions. A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0104] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0105] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a carboxypeptidase protein or anti-carboxypeptidase antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0106] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration, the agent can be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the GI tract by known methods. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0107] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0108] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0109] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0110] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0111] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form” as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0112] Anti-cardiopathic compounds identified by the methods of this invention may be used in the treatment of human individuals.

[0113] The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL Example 1 Generation of Transgenic Rabbits

[0114] On day 1 a New Zealand White doe was superovulated with 150 U pregnant mare serum gonadotropin delivered subcutaneously under the scruff of the neck. On day 3, the donor doe and a recipient doe received 150 U of human choriogonadotropin administered into an ear vein. The donor doe and a nontransgenic buck were mated. On day 4, the eggs were harvested from the donor doe. To generate the transgenic α-myosin heavy chain ventricle-preferred expressing rabbits, the α-myosin heavy chain nucleotide sequence was operably linked to the β-myosin heavy chain promoter to yield the sequence set forth in SEQ ID NO:5.

[0115] Purified DNA comprising the desired transgene was injected into the pronuclei of viable eggs. The viable eggs were transplanted into the fallopian tube of the pseudopregnant recipient doe. The recipient doe was moved to a nesting cage 2 to 3 days before the expected delivery date.

[0116] Transgenic offspring were identified by PCR and genomic Southern analysis using ³²P-labelled oligonucleotide probes corresponding to the human growth hormone sequences that were incorporated into the transgenic construct. The founder rabbits were up to 5 months (females) or 6 months (males) before a breeding program was established. Diploid copy number was determined with DNA dot blots.

Example 2 Cardiac Preferred Expression from the β-Myosin Heavy Chain Promoter

[0117] Expression of the CAT reporter gene under the control of the β-myosin heavy chain promoter (SEQ ID NO:2) was analyzed by ELISA. Transgenic rabbits comprising the β-myosin heavy chain promoter operably linked to the CAT reporter gene were prepared using the method described elsewhere herein. Four stable transgenic lines were established. The genomes of lines 415, 428L, 428M, and 428H contained two, fourteen, twenty-four, or thirty-nine copies of the transgene, respectively.

[0118] Tissues were dissected from multiple animals in the F2 generation of each transgenic line. Apex, left ventricle, right ventricle, left atria, right atria, diaphragm, soleus, bicep muscle, tibialis muscle, masseter muscle, tongue, stomach, small intestine, lung, liver, and spleen tissues were analyzed. The dissected tissues were frozen in liquid nitrogen. Proteins were isolated by tissue homogenization in 200-400 μl 0.25M Tris pH 7.8 with a Tekmar homogenizer (Tekmar Co). The homogenate was incubated at 65° C. for 10 minutes, then centrifuged for 10 minutes at 12,000 rpm in a tabletop microfuge. The supernatant was transferred to a new tube. The total protein concentration was determined by the Bradford method. The ELISAs were performed with a microtiter kit according to the manufacturer's instructions (Boehringer-Mannheim). The results are reported in pg CAT/μg total protein (FIG. 1).

Example 3 Assessment of Myosin Isoform Expression

[0119] To analyze transgene expression, mice were sacrificed by CO₂ asphyxiation. RNA was extracted using TriReagent® (Molecular Research, Inc.) according to the manufacturer's protocols. Two-fold serial dilutions of the RNAs starting with 8 micrograms were applied to nitrocellulose paper. Transcript-specific oligonucleotide probes for alphα-myosin heavy chain and glyceraldehyde phosphate dehydrogenase (so that any minor variations in loading could be accounted for) were end-labeled with ³²P-ATP and hybridized under standard conditions for 5 hours. Transcript levels were corrected for background and normalized to GAPDH signal intensity. All hybridization signals were quantified on a STORM® Phosphor Imager (Molecular Dynamics). The results from one such experiment are presented in FIG. 2, Panel A.

[0120] Total or myofibril protein samples were loaded onto a 7.5% SDS-PAGE gel and resolved by electrophoreses at 120 volts for 2 hours. Proteins were transferred onto nitrocellulose at 4° C. overnight. Western analyses were performed using an alpha myosin-specific antibody. The results from one such experiment are presented in FIG. 2, Panel B.

Example 4 Echocardiographic Analysis of Transgenic Rabbits

[0121] Transgenic rabbits from the F1 generation, prepared as described above, were aged 2-12 months before physiological analysis by echocardiography and/or 5-15 months for cardiac catheterization. Each rabbit was sedated with ketamine and the chest was shaved. Echocardiography was performed using a Hewlett-Packard 5500 Ultrasound System and a 7.5 MHz transducer. Contrast echocardiography was performed using intravenous Optison (Mallinckrodt). The 2-D and M-mode images were recorded on videotape and analyzed off-line by methods known to one of skill in the art. (See, for example, Schiller et al. (1989) J. Am. Soc. Echocardiogr. 2:358-367, herein incorporated by reference.)

Example 5 Cardiac Catheterization of Transgenic Rabbits

[0122] Transgenic rabbits of the invention were initially sedated with ketamine then anesthetized with isoflurane. Femoral access was obtained via cutdown and a 4 Fr sheath (Cook) was placed in the artery. A 4 Fr pigtail (Cook) was advanced into the sheath and positioned in the left ventricle. Pressure measurements and the electrocardiogram were recorded with a Prucka Cardio Lab 4.11 physiologic monitoring system (GE-Marquette). Contrast angiography was performed with Optiray 350 (Mallinckrodt) contrast diluted 1:1 with normal saline using a Liebel-Flarsheim Angiomat Illumena Digital Injection System (Mallinckrodt). Cineangiography was recorded with an OEC Series 9800 Digital Cardiac Imaging System (General Electric) in the left axial oblique and right axial oblique projections.

[0123] Following the procedure, the catheters were withdrawn, the femoral artery ligated, and the incision closed. The rabbits recovered from anesthesia before being returned to their cages.

Example 6 Assessment of Myosin Isoform Activity

[0124] Ventricles and atria were isolated from transgenic and nontransgenic rabbits. Cardiomyocytes were obtained from the ventricular and atrial tissue. The cardiomyocytes were lysed and used in ATPase assays. Reaction mixtures comprising cardiomyocyte lysates, ³²P-ATP, and salts were prepared. The assays were initiated with 10, 20, 40, or 80 μmol actin. The reactions were quenched. Reaction products were resolved and the nmol of inorganic phosphate (Pi) per minute per milligram of total protein in the reaction was determined. Results of such an experiment are presented in FIG. 3. Non-transgenic atrial tissue contains primarily the α-myosin heavy chain isoform. Non-transgenic ventricle tissue contains primarily the β-myosin heavy chain isoform. Transgenic ventricle tissue contains both the α and β myosin heavy chain isoforms.

Example 7 Induction of Cardiomyopathy by Heart Rate Elevation

[0125] Pacemakers were modified and implanted in twelve age-matched rabbits (5 transgenic and 7 non-transgenic littermates), as shown in FIG. 4. Five to seven days after surgical implantation of the pacemakers, rapid VVI pacing was initiated at 300 beats per minute (bpm) for 10 days. The pacing rate was then increased to 340 bpm for 10 days, followed by 10 days at 380 bpm. All 5 transgenic animals survived the pacing protocol. One non-transgenic rabbit died with a noticeably dilated heart after the pacemaker rate was increased to 380 bpm. The surviving animals did not exhibit signs of overt distress consistent with congestive heart failure. M-mode echocardiograms were performed on the animals. M-modes of a transgenic (FIG. 4, Panel B) and non-transgenic (FIG. 4, Panel C) rabbit are indicated.

Example 8 Assessment of Response to Cardiomyopathic Stimuli

[0126] The shortening fractions of the transgenic and non-transgenic rabbits undergoing the previously described cardiac pacing protocol were determined. Shortening fractions were determined prior to implantation of the modified pacemaker and prior to each increase in cardiac rate. M-mode and Doppler echocardiography were performed as described elsewhere herein to assess left ventricular (LV) function and dimensions. Left ventricular percent fractional shortening, velocity of circumferential shortening, and left ventricular end systolic meridional wall stress were calculated. LV mass was calculated using M-mode LV measurements according to American Society of Echocardiography conventions and the modified American Society of Echocardiography-cube LV mass equation. Results from one such experiment are presented in FIGS. 5 and 6.

[0127] All publications, patents, and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications, patents, and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually incorporated by reference.

[0128] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

1 5 1 5190 DNA Oryctolagus cuniculus 1 ggatccacac aactgggctt caccccacca ggtgccccag ctcaactctg tcttctgtcc 60 cagcacccgc ccaccttccc aaaactaacc gtgctctatt tccttcccag agcttgaatg 120 aggaatagcc tggtgacgcc ttgatccgcc cagccctgag gacgacgcca gtgaagtccc 180 ttgtctggga gctcacatag cagcagcccc ttgggaagaa gcagaataaa tcagttttcc 240 tcgaagctga gatcctgcct ccagactctt cttcactgcc tgtcagccct gtgggggtgg 300 gggtccagtg ggtggggcct tggagtggga aaggtgggag aaattggtgg agggtgggtc 360 tttagggcat gaggggcagc tgcaagggcc agacctagga gcttcccggg atcctgtagg 420 gtctgagccc tctggggagc agccatggtc ttgtggactc tctttacctg ctccggccca 480 acataacaca gaggtgaccc gtctcctcac agccctctcc tggctcagag tttatcagag 540 ttcaagattt aggcaaacct gggcctatct accatggaca tccaccccca cctcactgat 600 aacacccagc gccagggcat ggggaggtct ggtatgaagg gggctgaaca gtaccctttc 660 tgcaacctct ggggtatgac ccacgagggc aggtgaggca aaggtgtcct gagccccagc 720 cccaacagtc tcagaggaca caagcccttc cagatgcagc cagtggctcc ccccgccaca 780 gctaggagcc gggcaccccg tgcacacctt cctgtcaccc tcggctccct ccagagcctg 840 cagccctcca agcaggtgtc cctccctcct ccccacatct tccactgtag cttccattcc 900 caagactttc ctcctctgga catgtaggag gatggcattc tttggcccat ttatggaaag 960 ccatctcaga cgggcagaag agagcctggg gagggtcaca tgtgagcagg actctgggca 1020 ggagaggaaa gacatgtccc cagagggctg aagccggggc agcagcagct ggggtggggt 1080 ggaagaaagg gcaggttaac cgcccccccc cctgcagtga caactcagcc ccttggagtg 1140 gctgccacag ctgggctgcc aagggtagga ctggggcagt gggatgtgga gggcagggcc 1200 ttgggagact gtgggactgt cccccacacc ccatcccaag aacctgagtg gcccctattc 1260 agcccccgtc tgaagctcgt ccaaacctgc cacacacacc gacgcacagc cctgttcctg 1320 ctgcacaccc tactctgagt ggcagccaga acaagggcct aggccaggca ggaggggata 1380 ccagtggccg agcacagcag gagaggtgag gggaagagaa aggaaacagg gaaggaagga 1440 gatacccagg gcagatgcaa aggacgagca ggcgtggggt gacaagcaca cgggaggaag 1500 ccgccgggaa tgaagaggcc tcttagacac acaagccctc acacccacct ccctgcacgc 1560 ctctcctccc ttctccctcc ccacatcatt ccccttccca ggagcaggtt cggagatgaa 1620 ggaagaggtg gaggtcagag aggacacact tgtagggaag cccaggggtc tgagcaacca 1680 cagtgtgcaa gacagcaaga gagggaggtg ctgggagagt ggacagcagt gtcaggagag 1740 gcctggagag ccgggcccag gagaaggaga gagaaggaga ggcctggcca gggagccctt 1800 gagagggagc ctgggacaca ggcacctgca gagcagaggg aggtgacagt aggggaaagg 1860 acccgagtca ccttcagagg tcaggagagt ctggaaagca gaggaaccag ggggtggaag 1920 ggaggtggcc aaggagcccg gggcaggatg aggaggcaga gagctcagag gagacagagc 1980 cttaagtcag acccagaccc aggctcaggc agacccagga gaatccgagg ccaagtctgc 2040 ctttgagacc gggaaccagg cagggggaga ggacacagag acagagacat ggggaggcaa 2100 gcaggagagg ggcggcaagc cctgcctccc tgtcccccta cctttggcca gagtatccgt 2160 cccgtgccct cacactccag ggcctccagc agaatgcgga gctgatttgg gtggcagtgg 2220 agacagcgtg gacagcagag gtgtatggga acgccaggac agaggagggg gcccagggaa 2280 ggaagagggc aaaccaggcc agaccgggcc cgagcccaga gccaggctaa ccccttcctt 2340 ctacctcctt ccctaggagg gcaggcactg cctgcccacc cctcagcccc gccccctacc 2400 acctctccca agtttggtct gctcagggcg cagggttctc ccgaggacaa agcctggtct 2460 ttgtcacctg gaccttaccc aggctgacct ggtattccag ccccttatca ggtccccagg 2520 gggatgggaa ccaggcagtg acgcaccagg ccacgggata acccccagct tgtgcactgg 2580 ggcctcaagt gacctagagc tagagacagg tggcctgcat cccctgaggg caacggtttg 2640 gcatgtgcac ctgcaggaga tgggaatggc cggtcaactc aggtccctcc aaggacactg 2700 agtctggggt ccaagtcccc cagagagaga tgtgtctctg agccccgtaa taggcagcca 2760 gcatcctagg gggctgacaa ccttgggggg aaccccatct tcacggcaag tgctcccacc 2820 cagagaagct gacccctgcc tgtcctaccc acctccacac cctggagcta tatcgagagg 2880 tgtcagtgga taggggtggg aggggagctg aggcagtatt cttgggtgtg agggtgtggg 2940 ggaaagccag ggcaggagag tctggctttg tcttctgaac acaatgtcca cttagtcaca 3000 acaggcacgg cctgttgaag acccgacacc taccgcctct gagaggggac agcctgcagg 3060 atggaggagg agtaccttga gggctgggtg cttgaggacc ccccccccca aagacaggca 3120 tgggagtgtg agctcaggag gggatagcag gcttctatct gggaaggggg cagactacag 3180 agccccctcc ccccaaccct gcacccccct gcagccctgt ggaacgcaga gccagagccc 3240 aattggtgta aatccccagg cctgtctggc gccccagcca tcctcggcag cacctgcacc 3300 ctctggcagc ctggagaggc ggaagggagc ggcccccacc cccacccctg ctccctcagg 3360 cccggggatt agtgcagaag gtggcagcag gagggtaaaa gcctttgcgt gcagatgtga 3420 gcatcggcct gctggaaagc acgcagggat ctctgtaagc tgaagtgtga aatctgcatg 3480 tgtgtctggt caagtctgca cgcgagggtg ctggaccaag ggtctgtgcg caggtgtgcc 3540 tgaggcagcg tggagaattc cttccactgg gtgatgggtt tgcatgaggg ccactgtatg 3600 gggagcaccg gggaagtgct ggggctccag atgcattccc aagcaaagca gccttgagtc 3660 ctctgtcaga cacctgcctg ggaatagaag cccaggcaca gcgtgtgtgc agagttgggg 3720 caggacagag agggaaactg agtctggagc tggctagtag acgcctgctc cagctcacag 3780 gtccaggtct gagagtgtcg ggagacactt gcagcctggg ctgtgtgaag acaggcctgg 3840 gtaaatggga gagggtaggg gacaagggag ggaaactgca gctggggggc aggggacaag 3900 cattcgtcct atatgaaaag gtgaccctca ccccagtgtg ctcaactcac ccttcaggtt 3960 aaaaataacc gaggtaaagg ccatggtggg gcgggggagg tggtggagaa ggtcctgtct 4020 tcccactatc tgcccatcag cgctctggag gggcggaatg tgctcaagga ctaaaaaaag 4080 gccctggagc ccgaggggct ggggcagcag acctttcatg ggcaaatctg ggggccctgc 4140 cgtcctcttg tcacctccag agccaaggga tcaagggagg aggagccagg cagggagaga 4200 ggtgggaggg ggtccctccg gaagggctcc aaatttaggc aagggggtgg gggaagtggc 4260 atataaagga gctgcagcgt tgagggcagc cagactcctg cagcccaggt aagtgtggtt 4320 tgtgcagggg cactgtgcag ctgtgcacag ggaccctgcc ttcctgggag tgagctgcag 4380 ggcaggcggg ggcccacggg ttctgctgga agcgcccttc tccagccctg tggcaggtcc 4440 atgagaagcg cgactcctgt ctcctgtctc tctggttccc tgcccggttc tcagcacttg 4500 ctccctcctt tgggtggctt cctgcccgtt ggccctgtgc tgctttgcct ccctgtcttg 4560 gtcagcactt gtcccagtcc tcaatctccg tctccctcct tccttgccct cccttcgtgc 4620 ctgtgtgttc ttttctccct gcctttctct gtttctgtct ctgcttccac acccctgccc 4680 tcccacattc actcactctg catcccttcc tttcttccta ctccctgccg gtccaccctg 4740 ctggtgtctg tcggctctct gggctgggcc tcctcgtccc atcacttgtc tccatgattc 4800 tcttctctgc actttgtggc tcctgctcct ccagtggttc agattctccg ggattccctg 4860 tgaggagaga gtcaggtgag cggcacccag tctcctctgc agacagcaga gcaggctttc 4920 tccgggagcc aggtccaccc cctggcaacc ccaggcactc cttcccccca tgccgacctc 4980 ttacaaagat cccccctcag ccccagctga atggggtggg tggccccagg cagatccttt 5040 cacctgggta atgagaggag agcaataggt cctggaaagg aggtggtggg gcaaggaatg 5100 ggaatgggaa agacagggtc acccacgaaa gcctgagtct gcctcgggag tcacaggacc 5160 ccctgtcttg gccccagggg agaggtcgac 5190 2 6921 DNA Oryctolagus cuniculus 2 ggatcccccc tcctcggccc ccagcttgct cccaggacag aacaacatgg atcatgctgt 60 gttgtcctga accagtctcc cctggttcct ggtgtgttgc ctttggcacc cctggatgag 120 gggaatgcct gtgagtcagg cgccatgaga tcccactgca gctgccatag agcctggcta 180 cagcaggggt cagtatggca tctggtgggc tgaccaatcg gaacccctct gcagggaggg 240 aggaggatga gacaggctga gctgggggct ggaatggtgt cactcctggc aagtccatca 300 gacacccatg gtctgtctca gaactggcta tggaaggtag cttgggctct gtgcaatctg 360 tttgcacaaa gatatatgca tacacatatg tgtctgcaaa ggtaggcatg tgtgcttgcg 420 tgcactcaaa tgcatttaag gggtagggta gagctggggg tgggggacag gcagtggctc 480 tggggaggtc tgcttaagga ggtagagccc ttaccaaaga aatgaagtac tgggggctgg 540 cactgtgtgg catagtgggt aaaagctgcc acctgccatg ctggcaaccc atgtgggcgc 600 cagttcgagt cctggccgct ccacttccga tccagctttc tgccatggcc tgggaaagca 660 gtggaagatg gcccaagtcc ttgggaccat gcacccacgt gagagacctg gaagaagctc 720 ctggctcctg gctttggatc ggcgcagctc tggccgttgt ggccaatcgg ggagtgaatc 780 aatgggcgga agacctctct ctctctctct ctctctctct ctctctctct ctctctccgc 840 ctctccttct ctctgtataa ctctgacttt caaataaata aatcttaaaa aaaaaaaatg 900 aagtcctgta atccctttcc caggggagaa gactgatgat ttctcagcca cttgggctcc 960 tcacaaagca attaccttca gctctgagta aatcccacgg tctccatatc ctgtgctggt 1020 ccaggtgtgg cggccacagg atgctgcccc aagaacacct gtggacagag cacaggttct 1080 caggaggagc agagggagca gacatctgct ctgtgtgccc agcacagaga cagcagtgtg 1140 cagggatcct ggcttggaca caaatgcatc tggcaggtga cccaaggatg ctgattttcc 1200 atttgcccga tgatttcaca tcataacacc ttggccattc tccccacaga gtttctagac 1260 ccctgcagcc tacgattggg ctggctccag cgcaggtgtg gatgtgactg ctgaaggagc 1320 acgatcgacc cagggctgga tctgcccctc tcctgggggc ctggcttagt ctgcctccgc 1380 tctacagccc gatgcccctc tcctgggggc ctggcttagt ctgcctccgc tctacagccc 1440 gattcccaga ccctagggcc agccagctct accagggtgc accactaggg tccctaagac 1500 cttcaggcag gacatgaaaa ccagttagct ggtgagtggc cctaggttcc caactggtgt 1560 cctggtggat gtcaccattg gacctgggcc aactcctggt gggccccaag acagcactgg 1620 cctgtgggga gggccgttct gtgggtctca gtcaggcagt ggtggccctc ctggctaagg 1680 gctgggtctt ggagggcctg cgtaacttgg gctcttgacg tgatgtttcc actggcagcc 1740 atgggctggg tacaggagac cataggactg cagaatacct gaccagcccc ggcccagacc 1800 atcccttgag ccagatggac ttagtgaggc tgggggacaa agaactgccc ccacccgcca 1860 actgcagtct gacttcagtg ggttcgtgct cctgagggtg agaggagccg tttggtgagt 1920 gcctaccacg tgtcacgtgt gcactacacc ctgtacccac acaatggtca caacaaccct 1980 gggaggtaaa tggaccatgg ccacactaca gatgacaaga ctgtctcaga gaggccctgt 2040 gactaaccca gagcacatgg ccagaaaacg gaggggctgg ctttcaaaac aactgaccga 2100 agctcccagg ctgcccctca catggtcctg aggcctgcag ccctggcgtc cagactgccc 2160 actccccaca aagctcctcc aaacactcta agatggggaa gctctgtctt cccaaaccac 2220 tgcaagctaa accgagccat ccctgcaact gtccactgtc gacattgtgg agcagggaag 2280 cgagtgtggg gtggagggcc gaggtacaaa agatcttaga ggccgcagga agacaaaagc 2340 atgacaagaa ggagcagctg tttgtaaggg aaacttgaga ccggcacaaa gcccagctcc 2400 ctaatcccag gctcctgtgg agccagggcg ggcccccaag gtcagggatc ctaggggcag 2460 gcagatggca gatcggcctc caggcccggg tggggaccca ctcccatgtt cacgaacaac 2520 tgggggccca ttgtcctttc cgggttaagt ccccttcctc tagtgcccca ctctgctctc 2580 ttccctttgg gtttcggggg tcccttccag cttccttctt tctgtgcggg gtccctttta 2640 gtgtgcccta cttcaccccc tccccaattc ctgggagtaa ttttagcaac ttttcctctg 2700 aactgccgct ggcatggtca cagcaaatgg cccctgtttg ggcctgacac tcgatcaggg 2760 tggtgacaga gcccagacaa agcaggcaca gagcccgggg aggggggaca ggagacagat 2820 caccttcctt ccactccagg ccttatttgg tctaccttgg tgaagctgcc ctccctccag 2880 ccccttttat ttatagcctt ttgctctgct ctcctttgtc ttgtcggcta tcactctgca 2940 gtgccctctg cacaaccccc ctcctccccc ctcccctcca tggggccctg gcccctcact 3000 ctccctctag gaatgtgggt gtgtacacag ggcaccagct ccaagctcag gcccgaactc 3060 cacttctctc aactgctgaa tggagcttct cacgggaggg gtctttctct ggtcgctctg 3120 gctagaacaa tgcccagtgc gcagcaggct tccagaagca ctcgctgagt gaggaagtct 3180 gcaggctgct gtccccagat ggcagcaggc agaagcaaga gaagcaccgt ggagccaagg 3240 gcaggtgctg gaggggctgg gacgtcagac cccactgcca ccactaccac cacctaagcc 3300 tggagttagg ggagtgagtt ctattgtgca agagggcttg gagactgaac accaatgctg 3360 atacaccgat gacccagagc cttccagact taaaaggaag cacatgaagc atgatccttt 3420 actaggtgca aaaacagctc ctgcaaaggg ttcaaccgag gctcaagcat cttctgtgtg 3480 tcttcattgc ctgtacctgc tcctgagtcc tgggaactcg gggaaggggg cagccccctt 3540 ctttgcttag gtaaccagaa gggacggacg caagggcttg ctgtccatca ccagtccctg 3600 aggcccctga gtcctcggca cctgcagggc ctggccagga ccctcagcgt ctgcagtcag 3660 ggctttcact ggtgcaggct cagcttcagc agctgcaggc ccacgggtca tggtccaccc 3720 cacccccgcc cgtctgcacc ctgaacacac agtcgcttgt ggttctcaga cctcgccttg 3780 gttaccacgc agcccccaca gaagcccctc ctggagtttc tctccccagc tgtgcccacc 3840 ccaccttcaa catgtacctg atccgcaccc catcccccag gcctgcctct ccttccaagc 3900 tgacagccaa tcagatggat taatccgcac gcgcccaaga gcctcctggg aagaagggga 3960 ggggggtgga tttcaaaacc aaaccacgca gcggttgcct ggacacgaag ccagtcaggc 4020 ttgcctgcaa gagccaggct gtgctctgct cagagcctgc gctccggctc ccgctcctcc 4080 attcccttgc cctgcccgcc tctcagcctc actgtagaac accagtcgca tccaggtctg 4140 ggaagaggtc acaccgctgg aggaacagct gtcctggttc agggtctcct agcttagggc 4200 agctgtgcga tctcccactc ctggggcggg ggtcacctag tagctggggg cgcagaattg 4260 ggaagacaag tcaggcgcgg ggctgactgt gcatcttagt cctgcgctga ctaggaccat 4320 ccagcactgg gccccgagct ctgcacacag tatgtcttcc ctccttccca ggactccctc 4380 cacaggctgc tgctatttcc ccgccctgat tagctgggtg accttaaacc catacttccc 4440 ctctccataa aacgaaaagc ttggacggat aaagacctgt ctggctctgg gactcagtga 4500 tctcaacaca tcgcctgctg atccaaggaa atcagggcct gagccagagg ccccatgtct 4560 tagctccctg gtcatcgtcc gcgcccctta gcgaagcact ctccctccag ctgcccccct 4620 ccagcccctg gttctgccct gccctccctg gagctgagac ttagtccctt ttccatctca 4680 cagttggatg caggctccag gccaggaaag cagggaaatt tcccgttgca gaaacggggc 4740 caggtcagcc ttggaggctg ggggcctaag gggcagcagc atgaggggcc cacagtgccc 4800 tgtgggagag ccagggcctg cctgcctgag gtcacactgg tggtcctggt cagttccctc 4860 tcccacaggc agtggaatgc gaggagatat tttctgctgc acgttgagcc accccgcccc 4920 ctggaactca gaccctgcac accccatgcc ataacaatga cgaccacttc caattgtttc 4980 ctggcccgag ggggagggga gctctctggg agggggggcc ctgggggaaa tgcttccagt 5040 gacaacagcc ctttctaaat ccggctaggg actgggtgca ggtgggggtg ggggcgccct 5100 gctgccccat atatacaacc cctgaggcca ggtctggctc tcagctctct cctgctctgt 5160 gtgtctttcc ttgatgttct caggtaggag cggggagaag ggggctccag gttaggaagg 5220 ggctccccca ggaacagcaa gcttcatcag ggctttgtgc agagtcccag gtccggtcgt 5280 tgagcacacg tgtgcaggtt acacacccgt ggatgtgcca ctgagtgtga cgctcctgta 5340 ttccctgggg aaggtgtctg ggtctgagag tgtgggaacc aaatgaatga gtatgtgtgt 5400 gtgtgtgtgt gtgtgtgtac aagcatgtgc agtcggcagg tgagggaggg gtgtgcctca 5460 ctgtctgacg cagcgagtat tgatgatcgt gcctgagtac gagcagaatc ttttgggagt 5520 gggggggaat ggtgtagaat gattgtacag gaagtgtgga cgcttccaag ctagtcctga 5580 gaaccatctg tccatgcaca tggaggggct tgcctgtgcg tcgggagtca cgaccgctgt 5640 cgtgtgcgtg ccccctgcag aaggcgctcc caggcatgtg ggtgtggggc ttgggtcctt 5700 ctacactaaa gcataggcag ccacatgagc ctgcgtcccc ccacccaggc acataaacat 5760 gcggctccat agggtacctt agggggcggg ttctgtggcc caggaggcgg cctctgtgtg 5820 tgtgagacgt gtgcaagagc aggcatgcat ggtcatgggg gaggtgcagg gtgctcagct 5880 gtgtggtggg tgtgtctaag agaggacacc tgtcgtgtcc acaaagtctg acaatgaatg 5940 ggccagaaaa caactggctt tggagtgggg agagaggggc ttgaggctca gctctaccac 6000 ttaccattta tgctcttgaa taagcaaatc ctgtcacctt ggtttccccg tctgatgcat 6060 gggatgagaa ctgagaggag agtttgtgga ctgcacagca ctgagcaagt gtgaccatta 6120 gctgtgtccc agatagttca aagcaagtct cactagaagg ctatgagcgt ctcccaggag 6180 tgcggaaacc tgttagaact ggtccttggg gcagcaggga acagagctgg gaaaacaaga 6240 tgggagccgg gaagctgact tccagttcca gctgctgttt aggtctgggg gagagcagat 6300 gctgggagac agtcggggga agcgggaggt ggcacgggct aggatgggcc gcagcctgct 6360 ctgacacggc ctcttccctc tccccaggtc ccccgcaggc ctgagtcccc ttcctcatct 6420 gtagacacat ttgagaagcc aaggtaagag aagctgaagg gagagctgca aagactgggc 6480 gtgtgagtcc tgaggccagg ctgtggaacc ctggcttccg tcctgccttg gtggggacat 6540 cctaggtacc aggagcccct cactgtgact agtgagggat gcaggggcag gcaagggtca 6600 gaggtggatg tgagcagact cttgctcctc caagaagctc agagggttct ccccccaacc 6660 cccactccca cccccgcccc cgccttgggg agcctcagcc agaaccagtt agttgctcct 6720 tcctccatgg tgggctcgca aaactgctct tccagtaata ggacaagctc agacaacggg 6780 gacttgctgg ggacacgggt gacccctgaa tgcagagcta ggttttgggg ctcccaccga 6840 agggaagagc tcagggaggg gaaggcagag tggacagatg ggaggaacca gcttcttccg 6900 ctcactacag gtacagaatt c 6921 3 5886 DNA Oryctolagus cuniculus CDS (10)...(5827) 3 gaattcaag atg gat gac tcc cag atg gcc gac ttt ggg gcg gca gcc cag 51 Met Asp Asp Ser Gln Met Ala Asp Phe Gly Ala Ala Ala Gln 1 5 10 tac ctc cgc aag tcc gag aaa gag cgt cta gag gcc cag aca cgg cct 99 Tyr Leu Arg Lys Ser Glu Lys Glu Arg Leu Glu Ala Gln Thr Arg Pro 15 20 25 30 ttc gac atc cgc act gag tgc ttt gtg ccc gat gac aag gag gag ttc 147 Phe Asp Ile Arg Thr Glu Cys Phe Val Pro Asp Asp Lys Glu Glu Phe 35 40 45 gtc aag gcc aag atc gtg tct cgg gag gga ggc aag gtc acc gcc gaa 195 Val Lys Ala Lys Ile Val Ser Arg Glu Gly Gly Lys Val Thr Ala Glu 50 55 60 acc gag aac ggc aag acg gtg acc gtg aag gag gac cag gtg ttg cag 243 Thr Glu Asn Gly Lys Thr Val Thr Val Lys Glu Asp Gln Val Leu Gln 65 70 75 cag aac cca ccc aag ttc gac aag atc gag gac atg gcc atg ctg acc 291 Gln Asn Pro Pro Lys Phe Asp Lys Ile Glu Asp Met Ala Met Leu Thr 80 85 90 ttc cta cac gag ccc gct gta ctc tac aac ctc aag gag cgc tac gcg 339 Phe Leu His Glu Pro Ala Val Leu Tyr Asn Leu Lys Glu Arg Tyr Ala 95 100 105 110 gct tgg atg att tac acc tac tcg ggc ctc ttc tgc gtc acc gtc aac 387 Ala Trp Met Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Thr Val Asn 115 120 125 ccc tac aag tgg ctg ccg gtg tac aat gca gag gtg gtg gcc gcc tac 435 Pro Tyr Lys Trp Leu Pro Val Tyr Asn Ala Glu Val Val Ala Ala Tyr 130 135 140 cgg ggc aag aag agg agc gag gcc ccg ccc cac atc ttc tcc atc tct 483 Arg Gly Lys Lys Arg Ser Glu Ala Pro Pro His Ile Phe Ser Ile Ser 145 150 155 gac aac gcc tat cag tac atg cta aca gat cgg gaa aac cag tcc atc 531 Asp Asn Ala Tyr Gln Tyr Met Leu Thr Asp Arg Glu Asn Gln Ser Ile 160 165 170 ctc atc acc gga gaa tcc ggg gcg ggg aag aca gtg aac acc aag cgt 579 Leu Ile Thr Gly Glu Ser Gly Ala Gly Lys Thr Val Asn Thr Lys Arg 175 180 185 190 gtc atc cag tac ttt gcc agt att gca gcc att ggt gac cgg ggc aag 627 Val Ile Gln Tyr Phe Ala Ser Ile Ala Ala Ile Gly Asp Arg Gly Lys 195 200 205 aag gac aac gtc aat gcc aac aag ggc acc ctg gag gac cag atc atc 675 Lys Asp Asn Val Asn Ala Asn Lys Gly Thr Leu Glu Asp Gln Ile Ile 210 215 220 cag gcc aac cct gcc ttg gag gcc ttc ggc aac gcc aag acc gtc cgg 723 Gln Ala Asn Pro Ala Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Arg 225 230 235 aac gac aac tcc tcg cgc ttc ggg aaa ttc atc aga atc cac ttt gga 771 Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile His Phe Gly 240 245 250 gcc act gga aag ctg gct tct gcg gac ata gag acc tac ctg ctg gag 819 Ala Thr Gly Lys Leu Ala Ser Ala Asp Ile Glu Thr Tyr Leu Leu Glu 255 260 265 270 aag tcc cgg gtg atc ttc cag ctg aag gct gag agg aac tac cac atc 867 Lys Ser Arg Val Ile Phe Gln Leu Lys Ala Glu Arg Asn Tyr His Ile 275 280 285 ttc tac cag atc ctg tcc aac aag aag ccg gag ctg ctg gac atg ctg 915 Phe Tyr Gln Ile Leu Ser Asn Lys Lys Pro Glu Leu Leu Asp Met Leu 290 295 300 ctg atc aca aac aac ccc tac gac tac gcc ttc gtg tcc cag gga gag 963 Leu Ile Thr Asn Asn Pro Tyr Asp Tyr Ala Phe Val Ser Gln Gly Glu 305 310 315 gtg tcc gtg gcc tcc atc gac gac tcc gag gag ctc atg gcc acc gat 1011 Val Ser Val Ala Ser Ile Asp Asp Ser Glu Glu Leu Met Ala Thr Asp 320 325 330 aac gcc ttc gac gtg ctg ggc ttc agt tct gag gag aaa gtc ggc atc 1059 Asn Ala Phe Asp Val Leu Gly Phe Ser Ser Glu Glu Lys Val Gly Ile 335 340 345 350 tac aag ctg acg ggc gcc atc atg cac tac gga aac atg aag ttc aag 1107 Tyr Lys Leu Thr Gly Ala Ile Met His Tyr Gly Asn Met Lys Phe Lys 355 360 365 cag aag cag cgt gag gag cag gcg gag ccg gac ggc acc gaa gat gcc 1155 Gln Lys Gln Arg Glu Glu Gln Ala Glu Pro Asp Gly Thr Glu Asp Ala 370 375 380 gac aag tcc gcc tac ctc atg ggg ctg aac tcc gct gac ctg ctc aag 1203 Asp Lys Ser Ala Tyr Leu Met Gly Leu Asn Ser Ala Asp Leu Leu Lys 385 390 395 ggg ctg tgc cac cct cgg gtg aaa gtg ggc aac gag tac gtc acc aag 1251 Gly Leu Cys His Pro Arg Val Lys Val Gly Asn Glu Tyr Val Thr Lys 400 405 410 ggg cag aac gtg cag cag gtg tac tac tcc atc ggg gcg ctg gcc aag 1299 Gly Gln Asn Val Gln Gln Val Tyr Tyr Ser Ile Gly Ala Leu Ala Lys 415 420 425 430 gcc gtg tac gag aag atg ttc aac tgg atg gtg atg cgc atc aat gcc 1347 Ala Val Tyr Glu Lys Met Phe Asn Trp Met Val Met Arg Ile Asn Ala 435 440 445 acg ctg gag acc aag ctg ccg cgc cag tac ttc ata ggc gtc ctc gac 1395 Thr Leu Glu Thr Lys Leu Pro Arg Gln Tyr Phe Ile Gly Val Leu Asp 450 455 460 atc gcg ggc ttc gag atc ttt gac ttc aac agc ttt gag cag ctt tgc 1443 Ile Ala Gly Phe Glu Ile Phe Asp Phe Asn Ser Phe Glu Gln Leu Cys 465 470 475 atc aac ttc acc aac gag aag ctg cag cag ttc ttc aac cac cac atg 1491 Ile Asn Phe Thr Asn Glu Lys Leu Gln Gln Phe Phe Asn His His Met 480 485 490 ttc gtg ctg gag cag gag gag tac aag aag gag ggc atc gag tgg gag 1539 Phe Val Leu Glu Gln Glu Glu Tyr Lys Lys Glu Gly Ile Glu Trp Glu 495 500 505 510 ttc atc gac ttc ggc atg gac ctg cag gcc tgc atc gac ctc att gag 1587 Phe Ile Asp Phe Gly Met Asp Leu Gln Ala Cys Ile Asp Leu Ile Glu 515 520 525 aag ccc atg ggc atc atg tcc atc ctg gag gag gag tgc atg ttc ccc 1635 Lys Pro Met Gly Ile Met Ser Ile Leu Glu Glu Glu Cys Met Phe Pro 530 535 540 aag gcc acc gac atg acc ttc aag gcc aag cta tac gac aac cac ctg 1683 Lys Ala Thr Asp Met Thr Phe Lys Ala Lys Leu Tyr Asp Asn His Leu 545 550 555 ggc aag tcc aac aac ttc cag aag cca cgc aac gtc aag ggg aag cag 1731 Gly Lys Ser Asn Asn Phe Gln Lys Pro Arg Asn Val Lys Gly Lys Gln 560 565 570 gaa gcc cac ttc tcc ctg gtc cac tac gcc ggc acc gtg gac tac aac 1779 Glu Ala His Phe Ser Leu Val His Tyr Ala Gly Thr Val Asp Tyr Asn 575 580 585 590 atc ctg ggc tgg ctg gag aag aac aag gac cct ctc aac gag acg gtg 1827 Ile Leu Gly Trp Leu Glu Lys Asn Lys Asp Pro Leu Asn Glu Thr Val 595 600 605 gtg ggc ctg tac cag aag tcc tcc ctc aag ctg atg gcc acc ctc ttc 1875 Val Gly Leu Tyr Gln Lys Ser Ser Leu Lys Leu Met Ala Thr Leu Phe 610 615 620 gcc acc tat gct tct gcc gac act gcg gac act ggc aaa ggc aaa gga 1923 Ala Thr Tyr Ala Ser Ala Asp Thr Ala Asp Thr Gly Lys Gly Lys Gly 625 630 635 ggc aag aaa aag ggc tcg tcc ttc cag aca gtg tca gct ctc cac cgg 1971 Gly Lys Lys Lys Gly Ser Ser Phe Gln Thr Val Ser Ala Leu His Arg 640 645 650 gaa aat ctg aac aag ctg atg acc aac ctg agg acc acc cac cct cac 2019 Glu Asn Leu Asn Lys Leu Met Thr Asn Leu Arg Thr Thr His Pro His 655 660 665 670 ttc gtg cgc tgc atc atc ccc aat gag cgg aag gct cca ggg gtg atg 2067 Phe Val Arg Cys Ile Ile Pro Asn Glu Arg Lys Ala Pro Gly Val Met 675 680 685 gac aac ccc ctg gtc atg cac cag ctg cgt tgc aac ggc gtg ctg gaa 2115 Asp Asn Pro Leu Val Met His Gln Leu Arg Cys Asn Gly Val Leu Glu 690 695 700 ggc att cgc atc tgc agg aag ggc ttc ccc aac cgc atc ctc tac ggg 2163 Gly Ile Arg Ile Cys Arg Lys Gly Phe Pro Asn Arg Ile Leu Tyr Gly 705 710 715 gac ttc cgg cag agg tac cgc atc ctg aac cca gcg gcc atc cct gag 2211 Asp Phe Arg Gln Arg Tyr Arg Ile Leu Asn Pro Ala Ala Ile Pro Glu 720 725 730 ggc cag ttc att gac agc agg aag ggg gcg gag aag ctg ctg ggc tcc 2259 Gly Gln Phe Ile Asp Ser Arg Lys Gly Ala Glu Lys Leu Leu Gly Ser 735 740 745 750 ctg gac att gac cac aac cag tac aag ttc ggc cac acc aag gtg ttc 2307 Leu Asp Ile Asp His Asn Gln Tyr Lys Phe Gly His Thr Lys Val Phe 755 760 765 ttc aag gcc ggg ctg ctg ggg ctg ctg gag gag atg cgg gac gag agg 2355 Phe Lys Ala Gly Leu Leu Gly Leu Leu Glu Glu Met Arg Asp Glu Arg 770 775 780 ctg agc cgc atc atc acg cgc atc cag gcc cag tcc cgg ggc cag ctc 2403 Leu Ser Arg Ile Ile Thr Arg Ile Gln Ala Gln Ser Arg Gly Gln Leu 785 790 795 atg cgt gct gag ttc aag aag atc ctg gag cgc agg gat gcc ctg ctg 2451 Met Arg Ala Glu Phe Lys Lys Ile Leu Glu Arg Arg Asp Ala Leu Leu 800 805 810 gtc atc cag tgg aac atc cgg gcc ttc atg ggg gtc aag aac tgg ccc 2499 Val Ile Gln Trp Asn Ile Arg Ala Phe Met Gly Val Lys Asn Trp Pro 815 820 825 830 tgg atg aag ctc tac ttc aag atc aag cct ctg ctg aag agc gcg gag 2547 Trp Met Lys Leu Tyr Phe Lys Ile Lys Pro Leu Leu Lys Ser Ala Glu 835 840 845 acg gag aag gag atg gcc acc atg aag gag gag ttc ggg cgc atc aaa 2595 Thr Glu Lys Glu Met Ala Thr Met Lys Glu Glu Phe Gly Arg Ile Lys 850 855 860 gag tcc ctg gag aag tcg gag gcc cgc cgc aag gag ctg gag gag aag 2643 Glu Ser Leu Glu Lys Ser Glu Ala Arg Arg Lys Glu Leu Glu Glu Lys 865 870 875 atg gtg tcg ctg ctg cag gag aag aat gac ctg cag ctc caa gtg cag 2691 Met Val Ser Leu Leu Gln Glu Lys Asn Asp Leu Gln Leu Gln Val Gln 880 885 890 gcg gaa caa gac aac ctc aat gat gcc gag gag cgc tgc gac cag ctg 2739 Ala Glu Gln Asp Asn Leu Asn Asp Ala Glu Glu Arg Cys Asp Gln Leu 895 900 905 910 atc aag aac aag atc cag ctg gag gcc aag gtg aag gag atg aac gag 2787 Ile Lys Asn Lys Ile Gln Leu Glu Ala Lys Val Lys Glu Met Asn Glu 915 920 925 agg ctg gag gac gag gag gag atg aac gcc gag ctc act gcc aag aag 2835 Arg Leu Glu Asp Glu Glu Glu Met Asn Ala Glu Leu Thr Ala Lys Lys 930 935 940 cgc aag ctg gaa gac gag tgc tcc gag ctc aag aag gac att gac gac 2883 Arg Lys Leu Glu Asp Glu Cys Ser Glu Leu Lys Lys Asp Ile Asp Asp 945 950 955 ctg gag ctg acg ctg gcc aag gtg gag aag gag aag cac gca acc gag 2931 Leu Glu Leu Thr Leu Ala Lys Val Glu Lys Glu Lys His Ala Thr Glu 960 965 970 aac aag gtg aag aac ctg aca gag gag atg gct ggg ctg gac gag atc 2979 Asn Lys Val Lys Asn Leu Thr Glu Glu Met Ala Gly Leu Asp Glu Ile 975 980 985 990 atc gcc aag ctc acc aag gag aag aaa gct ctg caa gag gcc cac cag 3027 Ile Ala Lys Leu Thr Lys Glu Lys Lys Ala Leu Gln Glu Ala His Gln 995 1000 1005 cag gcc cta gat gac ctt cag gct gag gag gac aaa gtc aat act ctg 3075 Gln Ala Leu Asp Asp Leu Gln Ala Glu Glu Asp Lys Val Asn Thr Leu 1010 1015 1020 acc aag gcc aag ctc aag ctg gag cag cag gtg gac gat ctg gag gga 3123 Thr Lys Ala Lys Leu Lys Leu Glu Gln Gln Val Asp Asp Leu Glu Gly 1025 1030 1035 tcc ctg gag cag gag aag aag gtg cgc atg gac ctg gag cga gcc aag 3171 Ser Leu Glu Gln Glu Lys Lys Val Arg Met Asp Leu Glu Arg Ala Lys 1040 1045 1050 cgg aag ctg gag ggt gac ctg aag ctg acc cag gag agc atc atg gac 3219 Arg Lys Leu Glu Gly Asp Leu Lys Leu Thr Gln Glu Ser Ile Met Asp 1055 1060 1065 1070 ctg gag aat gac aag ctg cag ctg gag gag agg ctc aag aag aag gag 3267 Leu Glu Asn Asp Lys Leu Gln Leu Glu Glu Arg Leu Lys Lys Lys Glu 1075 1080 1085 ttt gac atc agt cag ctg aac agc aag atc gag gat gag cag gca ctg 3315 Phe Asp Ile Ser Gln Leu Asn Ser Lys Ile Glu Asp Glu Gln Ala Leu 1090 1095 1100 gcc ctc cag ctg cag aag aag ctg aag gaa aac cag gcc cgc atc gag 3363 Ala Leu Gln Leu Gln Lys Lys Leu Lys Glu Asn Gln Ala Arg Ile Glu 1105 1110 1115 gag ctg gag gag gag ctg gag gcc gag cgc act gcc agg gcc aag gtg 3411 Glu Leu Glu Glu Glu Leu Glu Ala Glu Arg Thr Ala Arg Ala Lys Val 1120 1125 1130 gag aag ctg cgc tcc gac ctg tcc cgg gag ctg gag gag atc agc gag 3459 Glu Lys Leu Arg Ser Asp Leu Ser Arg Glu Leu Glu Glu Ile Ser Glu 1135 1140 1145 1150 cgg ctg gag gag gcc ggc ggg gcc acg tcc gtg cag att gag atg aac 3507 Arg Leu Glu Glu Ala Gly Gly Ala Thr Ser Val Gln Ile Glu Met Asn 1155 1160 1165 aag aag cgc gag gcc gag ttc cag aag atg cga cgg gac ctg gag gag 3555 Lys Lys Arg Glu Ala Glu Phe Gln Lys Met Arg Arg Asp Leu Glu Glu 1170 1175 1180 gcc acg ctg caa cac gag gcc acg gcc gcc gcc ctg cgc aag aag cac 3603 Ala Thr Leu Gln His Glu Ala Thr Ala Ala Ala Leu Arg Lys Lys His 1185 1190 1195 gcg gac agc gtg gcc gag ctg ggc gag cag atc gac aac ctg cag cgg 3651 Ala Asp Ser Val Ala Glu Leu Gly Glu Gln Ile Asp Asn Leu Gln Arg 1200 1205 1210 gtg aag cag aag ctg gaa aag gag aag agc gag ttc aag ctg gag ctg 3699 Val Lys Gln Lys Leu Glu Lys Glu Lys Ser Glu Phe Lys Leu Glu Leu 1215 1220 1225 1230 gat gac gtc acc tcc aac atg gag cag atc atc aag gcc aag gca aac 3747 Asp Asp Val Thr Ser Asn Met Glu Gln Ile Ile Lys Ala Lys Ala Asn 1235 1240 1245 ctg gag aaa gtg tcc cgc acg ctg gaa gac cag gcc aac gag tac cgc 3795 Leu Glu Lys Val Ser Arg Thr Leu Glu Asp Gln Ala Asn Glu Tyr Arg 1250 1255 1260 atg aag ctg gag gaa gcc cag cgc tcc ctc aac gac ttc acc acc cag 3843 Met Lys Leu Glu Glu Ala Gln Arg Ser Leu Asn Asp Phe Thr Thr Gln 1265 1270 1275 cga gcc aag ctg caa acc gag aac gga gag cta gcc cgg cag ctg gag 3891 Arg Ala Lys Leu Gln Thr Glu Asn Gly Glu Leu Ala Arg Gln Leu Glu 1280 1285 1290 gag aag gag gcg ctg atc tcc cag ctg acc cgg ggc aag ctg tcc tac 3939 Glu Lys Glu Ala Leu Ile Ser Gln Leu Thr Arg Gly Lys Leu Ser Tyr 1295 1300 1305 1310 acc cag cag atg gag gac ctc aag agg cag ctg gag gag gaa ggc aag 3987 Thr Gln Gln Met Glu Asp Leu Lys Arg Gln Leu Glu Glu Glu Gly Lys 1315 1320 1325 gcc aag aac gcc ctg gcc cac gcg ctg cag tcg gcc cgc cat gac tgt 4035 Ala Lys Asn Ala Leu Ala His Ala Leu Gln Ser Ala Arg His Asp Cys 1330 1335 1340 gac ctg ctg cgg gag cag tac gag gag gag atg gag gcc aag gcg gag 4083 Asp Leu Leu Arg Glu Gln Tyr Glu Glu Glu Met Glu Ala Lys Ala Glu 1345 1350 1355 ctg cag cgc gtc ctg tcc aag gcc aac tcg gag gtg gca cag tgg agg 4131 Leu Gln Arg Val Leu Ser Lys Ala Asn Ser Glu Val Ala Gln Trp Arg 1360 1365 1370 acc aaa tat gag acg gac gcc atc cag cgc acc gag gag ctg gag gag 4179 Thr Lys Tyr Glu Thr Asp Ala Ile Gln Arg Thr Glu Glu Leu Glu Glu 1375 1380 1385 1390 gcc aag aag aag ctg gcc cag cgg ctg cag gac gcc gag gag gcc gtg 4227 Ala Lys Lys Lys Leu Ala Gln Arg Leu Gln Asp Ala Glu Glu Ala Val 1395 1400 1405 gag gcc gtc aac gcc aag tgc tcc tca ctg gag aag acc aag cac cgg 4275 Glu Ala Val Asn Ala Lys Cys Ser Ser Leu Glu Lys Thr Lys His Arg 1410 1415 1420 ctg cag aac gag atc gag gac ctc atg gtg gac gtg gag cgc tcc aac 4323 Leu Gln Asn Glu Ile Glu Asp Leu Met Val Asp Val Glu Arg Ser Asn 1425 1430 1435 gct gcc gcc gcc gcc ctg gac aag aag cag agg aac ttc gac aag atc 4371 Ala Ala Ala Ala Ala Leu Asp Lys Lys Gln Arg Asn Phe Asp Lys Ile 1440 1445 1450 ctg gcc gag tgg aag cag aag tac gag gag tcg cag tcg gag ctg gag 4419 Leu Ala Glu Trp Lys Gln Lys Tyr Glu Glu Ser Gln Ser Glu Leu Glu 1455 1460 1465 1470 tcc tcg cag aag gag gcg cgc tcc ctc agc acc gag ctc ttc aag ctc 4467 Ser Ser Gln Lys Glu Ala Arg Ser Leu Ser Thr Glu Leu Phe Lys Leu 1475 1480 1485 aag aac gcc tac gag gag tcc ctg gag cac ctg gag acc ttc aag cgg 4515 Lys Asn Ala Tyr Glu Glu Ser Leu Glu His Leu Glu Thr Phe Lys Arg 1490 1495 1500 gag aac aag aac ctg cag gag gag atc tct gac ctg acg gag cag ctg 4563 Glu Asn Lys Asn Leu Gln Glu Glu Ile Ser Asp Leu Thr Glu Gln Leu 1505 1510 1515 gga gaa gga ggc aag aat ctg cac gag ctg gag aag gtc cgc aag cag 4611 Gly Glu Gly Gly Lys Asn Leu His Glu Leu Glu Lys Val Arg Lys Gln 1520 1525 1530 ctg gag gcc gag aag ctg gag ctg cag tcg gcc ctg gag gag gcc gag 4659 Leu Glu Ala Glu Lys Leu Glu Leu Gln Ser Ala Leu Glu Glu Ala Glu 1535 1540 1545 1550 gcc tcc ctg gag cac gag gaa ggc aag atc ctc cgg gcc cag ctg gag 4707 Ala Ser Leu Glu His Glu Glu Gly Lys Ile Leu Arg Ala Gln Leu Glu 1555 1560 1565 ttc aac cag atc aag gcg gag atc gag cgg aag ctg gtg gag aag gac 4755 Phe Asn Gln Ile Lys Ala Glu Ile Glu Arg Lys Leu Val Glu Lys Asp 1570 1575 1580 gag gag atg gaa cag gcc aag cgc aac cac ctg cgg gtg gtg gac tca 4803 Glu Glu Met Glu Gln Ala Lys Arg Asn His Leu Arg Val Val Asp Ser 1585 1590 1595 ctg cag acc tcc ctg gat gca gag acg cgc agc cgc aac gag gcc ctg 4851 Leu Gln Thr Ser Leu Asp Ala Glu Thr Arg Ser Arg Asn Glu Ala Leu 1600 1605 1610 cgg gtg aag aag aag atg gag ggc gac ctc aac gag atg gag atc cag 4899 Arg Val Lys Lys Lys Met Glu Gly Asp Leu Asn Glu Met Glu Ile Gln 1615 1620 1625 1630 ctc agc cag gcc aac agg acg gcc tcc gag gcc cag aag cac ctg aag 4947 Leu Ser Gln Ala Asn Arg Thr Ala Ser Glu Ala Gln Lys His Leu Lys 1635 1640 1645 aac gcc caa gcc cac ctg aag gac acc cag atc cag ctg gat gac gcg 4995 Asn Ala Gln Ala His Leu Lys Asp Thr Gln Ile Gln Leu Asp Asp Ala 1650 1655 1660 gtc cgg gcc aat gac gac ctg aag gag aac atc gcc atc gtg gag cgg 5043 Val Arg Ala Asn Asp Asp Leu Lys Glu Asn Ile Ala Ile Val Glu Arg 1665 1670 1675 cgc aac gcg ctg ctg cag gcc gag ctg gag gag ctg cgg gcc gtg gtg 5091 Arg Asn Ala Leu Leu Gln Ala Glu Leu Glu Glu Leu Arg Ala Val Val 1680 1685 1690 gag cag acg gag cgg tct cgg aag ctg gca gag cag gag ctg atc gag 5139 Glu Gln Thr Glu Arg Ser Arg Lys Leu Ala Glu Gln Glu Leu Ile Glu 1695 1700 1705 1710 acc agc gag cgg gtg cag ctg ctg cac tcc cag aac acc agc ctc atc 5187 Thr Ser Glu Arg Val Gln Leu Leu His Ser Gln Asn Thr Ser Leu Ile 1715 1720 1725 aac cag aag aag aag atg gag tcg gac ctg acc cag ctg cag acg gaa 5235 Asn Gln Lys Lys Lys Met Glu Ser Asp Leu Thr Gln Leu Gln Thr Glu 1730 1735 1740 gtg gag gag gcg gtg cag gaa tgc agg aac gcc gag gag aag gcc aag 5283 Val Glu Glu Ala Val Gln Glu Cys Arg Asn Ala Glu Glu Lys Ala Lys 1745 1750 1755 aag gcc atc acg gac gcc gcc atg atg gcg gag gag ctg aag aag gag 5331 Lys Ala Ile Thr Asp Ala Ala Met Met Ala Glu Glu Leu Lys Lys Glu 1760 1765 1770 cag gac acc agc gcc cac ctg gag cgc atg aag aag aac atg gag cag 5379 Gln Asp Thr Ser Ala His Leu Glu Arg Met Lys Lys Asn Met Glu Gln 1775 1780 1785 1790 acc att aag gac ctg cag cac cgg ctg gac gag gcc gag cag atc gcc 5427 Thr Ile Lys Asp Leu Gln His Arg Leu Asp Glu Ala Glu Gln Ile Ala 1795 1800 1805 ctc aag ggc ggc aag aag cag ctg cag aag ctg gag gcg cgg gtg cgg 5475 Leu Lys Gly Gly Lys Lys Gln Leu Gln Lys Leu Glu Ala Arg Val Arg 1810 1815 1820 gag ctg gag aat gag ctg gag gcc gag cag aag cgc aac gcg gag tcg 5523 Glu Leu Glu Asn Glu Leu Glu Ala Glu Gln Lys Arg Asn Ala Glu Ser 1825 1830 1835 gtg aag ggc atg agg aag agc gag cgg cgc atc aag gag ctc acc tac 5571 Val Lys Gly Met Arg Lys Ser Glu Arg Arg Ile Lys Glu Leu Thr Tyr 1840 1845 1850 cag acg gag gag gac aag aag aac ctg ctg cgg ctg cag gac ctg gtg 5619 Gln Thr Glu Glu Asp Lys Lys Asn Leu Leu Arg Leu Gln Asp Leu Val 1855 1860 1865 1870 gac aag ctg cag ctg aag gtc aag gcc tac aag cgc cag gcc gag gag 5667 Asp Lys Leu Gln Leu Lys Val Lys Ala Tyr Lys Arg Gln Ala Glu Glu 1875 1880 1885 gcg gag gag cag gcc aac acc aac ctg tcc aag ttc cgc aag gtg cag 5715 Ala Glu Glu Gln Ala Asn Thr Asn Leu Ser Lys Phe Arg Lys Val Gln 1890 1895 1900 cac gag ctg gac gag gcg gag gag cgg gca gac atc gcg gag tcc cag 5763 His Glu Leu Asp Glu Ala Glu Glu Arg Ala Asp Ile Ala Glu Ser Gln 1905 1910 1915 gtc aac aag ctg cgg gcc aag agc cgc gac atc ggc gcc aag caa aaa 5811 Val Asn Lys Leu Arg Ala Lys Ser Arg Asp Ile Gly Ala Lys Gln Lys 1920 1925 1930 atg cac gac gag gag t gacgccgcct ccggaacccc gctcttgtta acccgcaata 5867 Met His Asp Glu Glu 1935 aacacgagtg cctgaattc 5886 4 1939 PRT Oryctolagus cuniculus 4 Met Asp Asp Ser Gln Met Ala Asp Phe Gly Ala Ala Ala Gln Tyr Leu 1 5 10 15 Arg Lys Ser Glu Lys Glu Arg Leu Glu Ala Gln Thr Arg Pro Phe Asp 20 25 30 Ile Arg Thr Glu Cys Phe Val Pro Asp Asp Lys Glu Glu Phe Val Lys 35 40 45 Ala Lys Ile Val Ser Arg Glu Gly Gly Lys Val Thr Ala Glu Thr Glu 50 55 60 Asn Gly Lys Thr Val Thr Val Lys Glu Asp Gln Val Leu Gln Gln Asn 65 70 75 80 Pro Pro Lys Phe Asp Lys Ile Glu Asp Met Ala Met Leu Thr Phe Leu 85 90 95 His Glu Pro Ala Val Leu Tyr Asn Leu Lys Glu Arg Tyr Ala Ala Trp 100 105 110 Met Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Thr Val Asn Pro Tyr 115 120 125 Lys Trp Leu Pro Val Tyr Asn Ala Glu Val Val Ala Ala Tyr Arg Gly 130 135 140 Lys Lys Arg Ser Glu Ala Pro Pro His Ile Phe Ser Ile Ser Asp Asn 145 150 155 160 Ala Tyr Gln Tyr Met Leu Thr Asp Arg Glu Asn Gln Ser Ile Leu Ile 165 170 175 Thr Gly Glu Ser Gly Ala Gly Lys Thr Val Asn Thr Lys Arg Val Ile 180 185 190 Gln Tyr Phe Ala Ser Ile Ala Ala Ile Gly Asp Arg Gly Lys Lys Asp 195 200 205 Asn Val Asn Ala Asn Lys Gly Thr Leu Glu Asp Gln Ile Ile Gln Ala 210 215 220 Asn Pro Ala Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Arg Asn Asp 225 230 235 240 Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile His Phe Gly Ala Thr 245 250 255 Gly Lys Leu Ala Ser Ala Asp Ile Glu Thr Tyr Leu Leu Glu Lys Ser 260 265 270 Arg Val Ile Phe Gln Leu Lys Ala Glu Arg Asn Tyr His Ile Phe Tyr 275 280 285 Gln Ile Leu Ser Asn Lys Lys Pro Glu Leu Leu Asp Met Leu Leu Ile 290 295 300 Thr Asn Asn Pro Tyr Asp Tyr Ala Phe Val Ser Gln Gly Glu Val Ser 305 310 315 320 Val Ala Ser Ile Asp Asp Ser Glu Glu Leu Met Ala Thr Asp Asn Ala 325 330 335 Phe Asp Val Leu Gly Phe Ser Ser Glu Glu Lys Val Gly Ile Tyr Lys 340 345 350 Leu Thr Gly Ala Ile Met His Tyr Gly Asn Met Lys Phe Lys Gln Lys 355 360 365 Gln Arg Glu Glu Gln Ala Glu Pro Asp Gly Thr Glu Asp Ala Asp Lys 370 375 380 Ser Ala Tyr Leu Met Gly Leu Asn Ser Ala Asp Leu Leu Lys Gly Leu 385 390 395 400 Cys His Pro Arg Val Lys Val Gly Asn Glu Tyr Val Thr Lys Gly Gln 405 410 415 Asn Val Gln Gln Val Tyr Tyr Ser Ile Gly Ala Leu Ala Lys Ala Val 420 425 430 Tyr Glu Lys Met Phe Asn Trp Met Val Met Arg Ile Asn Ala Thr Leu 435 440 445 Glu Thr Lys Leu Pro Arg Gln Tyr Phe Ile Gly Val Leu Asp Ile Ala 450 455 460 Gly Phe Glu Ile Phe Asp Phe Asn Ser Phe Glu Gln Leu Cys Ile Asn 465 470 475 480 Phe Thr Asn Glu Lys Leu Gln Gln Phe Phe Asn His His Met Phe Val 485 490 495 Leu Glu Gln Glu Glu Tyr Lys Lys Glu Gly Ile Glu Trp Glu Phe Ile 500 505 510 Asp Phe Gly Met Asp Leu Gln Ala Cys Ile Asp Leu Ile Glu Lys Pro 515 520 525 Met Gly Ile Met Ser Ile Leu Glu Glu Glu Cys Met Phe Pro Lys Ala 530 535 540 Thr Asp Met Thr Phe Lys Ala Lys Leu Tyr Asp Asn His Leu Gly Lys 545 550 555 560 Ser Asn Asn Phe Gln Lys Pro Arg Asn Val Lys Gly Lys Gln Glu Ala 565 570 575 His Phe Ser Leu Val His Tyr Ala Gly Thr Val Asp Tyr Asn Ile Leu 580 585 590 Gly Trp Leu Glu Lys Asn Lys Asp Pro Leu Asn Glu Thr Val Val Gly 595 600 605 Leu Tyr Gln Lys Ser Ser Leu Lys Leu Met Ala Thr Leu Phe Ala Thr 610 615 620 Tyr Ala Ser Ala Asp Thr Ala Asp Thr Gly Lys Gly Lys Gly Gly Lys 625 630 635 640 Lys Lys Gly Ser Ser Phe Gln Thr Val Ser Ala Leu His Arg Glu Asn 645 650 655 Leu Asn Lys Leu Met Thr Asn Leu Arg Thr Thr His Pro His Phe Val 660 665 670 Arg Cys Ile Ile Pro Asn Glu Arg Lys Ala Pro Gly Val Met Asp Asn 675 680 685 Pro Leu Val Met His Gln Leu Arg Cys Asn Gly Val Leu Glu Gly Ile 690 695 700 Arg Ile Cys Arg Lys Gly Phe Pro Asn Arg Ile Leu Tyr Gly Asp Phe 705 710 715 720 Arg Gln Arg Tyr Arg Ile Leu Asn Pro Ala Ala Ile Pro Glu Gly Gln 725 730 735 Phe Ile Asp Ser Arg Lys Gly Ala Glu Lys Leu Leu Gly Ser Leu Asp 740 745 750 Ile Asp His Asn Gln Tyr Lys Phe Gly His Thr Lys Val Phe Phe Lys 755 760 765 Ala Gly Leu Leu Gly Leu Leu Glu Glu Met Arg Asp Glu Arg Leu Ser 770 775 780 Arg Ile Ile Thr Arg Ile Gln Ala Gln Ser Arg Gly Gln Leu Met Arg 785 790 795 800 Ala Glu Phe Lys Lys Ile Leu Glu Arg Arg Asp Ala Leu Leu Val Ile 805 810 815 Gln Trp Asn Ile Arg Ala Phe Met Gly Val Lys Asn Trp Pro Trp Met 820 825 830 Lys Leu Tyr Phe Lys Ile Lys Pro Leu Leu Lys Ser Ala Glu Thr Glu 835 840 845 Lys Glu Met Ala Thr Met Lys Glu Glu Phe Gly Arg Ile Lys Glu Ser 850 855 860 Leu Glu Lys Ser Glu Ala Arg Arg Lys Glu Leu Glu Glu Lys Met Val 865 870 875 880 Ser Leu Leu Gln Glu Lys Asn Asp Leu Gln Leu Gln Val Gln Ala Glu 885 890 895 Gln Asp Asn Leu Asn Asp Ala Glu Glu Arg Cys Asp Gln Leu Ile Lys 900 905 910 Asn Lys Ile Gln Leu Glu Ala Lys Val Lys Glu Met Asn Glu Arg Leu 915 920 925 Glu Asp Glu Glu Glu Met Asn Ala Glu Leu Thr Ala Lys Lys Arg Lys 930 935 940 Leu Glu Asp Glu Cys Ser Glu Leu Lys Lys Asp Ile Asp Asp Leu Glu 945 950 955 960 Leu Thr Leu Ala Lys Val Glu Lys Glu Lys His Ala Thr Glu Asn Lys 965 970 975 Val Lys Asn Leu Thr Glu Glu Met Ala Gly Leu Asp Glu Ile Ile Ala 980 985 990 Lys Leu Thr Lys Glu Lys Lys Ala Leu Gln Glu Ala His Gln Gln Ala 995 1000 1005 Leu Asp Asp Leu Gln Ala Glu Glu Asp Lys Val Asn Thr Leu Thr Lys 1010 1015 1020 Ala Lys Leu Lys Leu Glu Gln Gln Val Asp Asp Leu Glu Gly Ser Leu 1025 1030 1035 1040 Glu Gln Glu Lys Lys Val Arg Met Asp Leu Glu Arg Ala Lys Arg Lys 1045 1050 1055 Leu Glu Gly Asp Leu Lys Leu Thr Gln Glu Ser Ile Met Asp Leu Glu 1060 1065 1070 Asn Asp Lys Leu Gln Leu Glu Glu Arg Leu Lys Lys Lys Glu Phe Asp 1075 1080 1085 Ile Ser Gln Leu Asn Ser Lys Ile Glu Asp Glu Gln Ala Leu Ala Leu 1090 1095 1100 Gln Leu Gln Lys Lys Leu Lys Glu Asn Gln Ala Arg Ile Glu Glu Leu 1105 1110 1115 1120 Glu Glu Glu Leu Glu Ala Glu Arg Thr Ala Arg Ala Lys Val Glu Lys 1125 1130 1135 Leu Arg Ser Asp Leu Ser Arg Glu Leu Glu Glu Ile Ser Glu Arg Leu 1140 1145 1150 Glu Glu Ala Gly Gly Ala Thr Ser Val Gln Ile Glu Met Asn Lys Lys 1155 1160 1165 Arg Glu Ala Glu Phe Gln Lys Met Arg Arg Asp Leu Glu Glu Ala Thr 1170 1175 1180 Leu Gln His Glu Ala Thr Ala Ala Ala Leu Arg Lys Lys His Ala Asp 1185 1190 1195 1200 Ser Val Ala Glu Leu Gly Glu Gln Ile Asp Asn Leu Gln Arg Val Lys 1205 1210 1215 Gln Lys Leu Glu Lys Glu Lys Ser Glu Phe Lys Leu Glu Leu Asp Asp 1220 1225 1230 Val Thr Ser Asn Met Glu Gln Ile Ile Lys Ala Lys Ala Asn Leu Glu 1235 1240 1245 Lys Val Ser Arg Thr Leu Glu Asp Gln Ala Asn Glu Tyr Arg Met Lys 1250 1255 1260 Leu Glu Glu Ala Gln Arg Ser Leu Asn Asp Phe Thr Thr Gln Arg Ala 1265 1270 1275 1280 Lys Leu Gln Thr Glu Asn Gly Glu Leu Ala Arg Gln Leu Glu Glu Lys 1285 1290 1295 Glu Ala Leu Ile Ser Gln Leu Thr Arg Gly Lys Leu Ser Tyr Thr Gln 1300 1305 1310 Gln Met Glu Asp Leu Lys Arg Gln Leu Glu Glu Glu Gly Lys Ala Lys 1315 1320 1325 Asn Ala Leu Ala His Ala Leu Gln Ser Ala Arg His Asp Cys Asp Leu 1330 1335 1340 Leu Arg Glu Gln Tyr Glu Glu Glu Met Glu Ala Lys Ala Glu Leu Gln 1345 1350 1355 1360 Arg Val Leu Ser Lys Ala Asn Ser Glu Val Ala Gln Trp Arg Thr Lys 1365 1370 1375 Tyr Glu Thr Asp Ala Ile Gln Arg Thr Glu Glu Leu Glu Glu Ala Lys 1380 1385 1390 Lys Lys Leu Ala Gln Arg Leu Gln Asp Ala Glu Glu Ala Val Glu Ala 1395 1400 1405 Val Asn Ala Lys Cys Ser Ser Leu Glu Lys Thr Lys His Arg Leu Gln 1410 1415 1420 Asn Glu Ile Glu Asp Leu Met Val Asp Val Glu Arg Ser Asn Ala Ala 1425 1430 1435 1440 Ala Ala Ala Leu Asp Lys Lys Gln Arg Asn Phe Asp Lys Ile Leu Ala 1445 1450 1455 Glu Trp Lys Gln Lys Tyr Glu Glu Ser Gln Ser Glu Leu Glu Ser Ser 1460 1465 1470 Gln Lys Glu Ala Arg Ser Leu Ser Thr Glu Leu Phe Lys Leu Lys Asn 1475 1480 1485 Ala Tyr Glu Glu Ser Leu Glu His Leu Glu Thr Phe Lys Arg Glu Asn 1490 1495 1500 Lys Asn Leu Gln Glu Glu Ile Ser Asp Leu Thr Glu Gln Leu Gly Glu 1505 1510 1515 1520 Gly Gly Lys Asn Leu His Glu Leu Glu Lys Val Arg Lys Gln Leu Glu 1525 1530 1535 Ala Glu Lys Leu Glu Leu Gln Ser Ala Leu Glu Glu Ala Glu Ala Ser 1540 1545 1550 Leu Glu His Glu Glu Gly Lys Ile Leu Arg Ala Gln Leu Glu Phe Asn 1555 1560 1565 Gln Ile Lys Ala Glu Ile Glu Arg Lys Leu Val Glu Lys Asp Glu Glu 1570 1575 1580 Met Glu Gln Ala Lys Arg Asn His Leu Arg Val Val Asp Ser Leu Gln 1585 1590 1595 1600 Thr Ser Leu Asp Ala Glu Thr Arg Ser Arg Asn Glu Ala Leu Arg Val 1605 1610 1615 Lys Lys Lys Met Glu Gly Asp Leu Asn Glu Met Glu Ile Gln Leu Ser 1620 1625 1630 Gln Ala Asn Arg Thr Ala Ser Glu Ala Gln Lys His Leu Lys Asn Ala 1635 1640 1645 Gln Ala His Leu Lys Asp Thr Gln Ile Gln Leu Asp Asp Ala Val Arg 1650 1655 1660 Ala Asn Asp Asp Leu Lys Glu Asn Ile Ala Ile Val Glu Arg Arg Asn 1665 1670 1675 1680 Ala Leu Leu Gln Ala Glu Leu Glu Glu Leu Arg Ala Val Val Glu Gln 1685 1690 1695 Thr Glu Arg Ser Arg Lys Leu Ala Glu Gln Glu Leu Ile Glu Thr Ser 1700 1705 1710 Glu Arg Val Gln Leu Leu His Ser Gln Asn Thr Ser Leu Ile Asn Gln 1715 1720 1725 Lys Lys Lys Met Glu Ser Asp Leu Thr Gln Leu Gln Thr Glu Val Glu 1730 1735 1740 Glu Ala Val Gln Glu Cys Arg Asn Ala Glu Glu Lys Ala Lys Lys Ala 1745 1750 1755 1760 Ile Thr Asp Ala Ala Met Met Ala Glu Glu Leu Lys Lys Glu Gln Asp 1765 1770 1775 Thr Ser Ala His Leu Glu Arg Met Lys Lys Asn Met Glu Gln Thr Ile 1780 1785 1790 Lys Asp Leu Gln His Arg Leu Asp Glu Ala Glu Gln Ile Ala Leu Lys 1795 1800 1805 Gly Gly Lys Lys Gln Leu Gln Lys Leu Glu Ala Arg Val Arg Glu Leu 1810 1815 1820 Glu Asn Glu Leu Glu Ala Glu Gln Lys Arg Asn Ala Glu Ser Val Lys 1825 1830 1835 1840 Gly Met Arg Lys Ser Glu Arg Arg Ile Lys Glu Leu Thr Tyr Gln Thr 1845 1850 1855 Glu Glu Asp Lys Lys Asn Leu Leu Arg Leu Gln Asp Leu Val Asp Lys 1860 1865 1870 Leu Gln Leu Lys Val Lys Ala Tyr Lys Arg Gln Ala Glu Glu Ala Glu 1875 1880 1885 Glu Gln Ala Asn Thr Asn Leu Ser Lys Phe Arg Lys Val Gln His Glu 1890 1895 1900 Leu Asp Glu Ala Glu Glu Arg Ala Asp Ile Ala Glu Ser Gln Val Asn 1905 1910 1915 1920 Lys Leu Arg Ala Lys Ser Arg Asp Ile Gly Ala Lys Gln Lys Met His 1925 1930 1935 Asp Glu Glu 5 12801 DNA Oryctolagus cuniculus misc_feature 2483, 3284 n = A,T,C or G 5 ggatcccccc tcctcggccc ccagcttgct cccaggacag aacaacatgg atcatgctgt 60 gttgtcctga accagtctcc cctggttcct ggtgtgttgc ctttggcacc cctggatgag 120 gggaatgcct gtgagtcagg cgccatgaga tcccactgca gctgccatag agcctggcta 180 cagcaggggt cagtatggca tctggtgggc tgaccaatcg gaacccctct gcagggaggg 240 aggaggatga gacaggctga gctgggggct ggaatggtgt cactcctggc aagtccatca 300 gacacccatg gtctgtctca gaactggcta tggaaggtag cttgggctct gtgcaatctg 360 tttgcacaaa gatatatgca tacacatatg tgtctgcaaa ggtaggcatg tgtgcttgcg 420 tgcactcaaa tgcatttaag gggtagggta gagctggggg tgggggacag gcagtggctc 480 tggggaggtc tgcttaagga ggtagagccc ttaccaaaga aatgaagtac tgggggctgg 540 cactgtgtgg catagtgggt aaaagctgcc acctgccatg ctggcaaccc atgtgggcgc 600 cagttcgagt cctggccgct ccacttccga tccagctttc tgccatggcc tgggaaagca 660 gtggaagatg gcccaagtcc ttgggaccat gcacccacgt gagagacctg gaagaagctc 720 ctggctcctg gctttggatc ggcgcagctc tggccgttgt ggccaatcgg ggagtgaatc 780 aatgggcgga agacctctct ctctctctct ctctctctct ctctctctct ctctctccgc 840 ctctccttct ctctgtataa ctctgacttt caaataaata aatcttaaaa aaaaaaaatg 900 aagtcctgta atccctttcc caggggagaa gactgatgat ttctcagcca cttgggctcc 960 tcacaaagca attaccttca gctctgagta aatcccacgg tctccatatc ctgtgctggt 1020 ccaggtgtgg cggccacagg atgctgcccc aagaacacct gtggacagag cacaggttct 1080 caggaggagc agagggagca gacatctgct ctgtgtgccc agcacagaga cagcagtgtg 1140 cagggatcct ggcttggaca caaatgcatc tggcaggtga cccaaggatg ctgattttcc 1200 atttgcccga tgatttcaca tcataacacc ttggccattc tccccacaga gtttctagac 1260 ccctgcagcc tacgattggg ctggctccag cgcaggtgtg gatgtgactg ctgaaggagc 1320 acgatcgacc cagggctgga tctgcccctc tcctgggggc ctggcttagt ctgcctccgc 1380 tctacagccc gatgcccctc tcctgggggc ctggcttagt ctgcctccgc tctacagccc 1440 gattcccaga ccctagggcc agccagctct accagggtgc accactaggg tccctaagac 1500 cttcaggcag gacatgaaaa ccagttagct ggtgagtggc cctaggttcc caactggtgt 1560 cctggtggat gtcaccattg gacctgggcc aactcctggt gggccccaag acagcactgg 1620 cctgtgggga gggccgttct gtgggtctca gtcaggcagt ggtggccctc ctggctaagg 1680 gctgggtctt ggagggcctg cgtaacttgg gctcttgacg tgatgtttcc actggcagcc 1740 atgggctggg tacaggagac cataggactg cagaatacct gaccagcccc ggcccagacc 1800 atcccttgag ccagatggac ttagtgaggc tgggggacaa agaactgccc ccacccgcca 1860 actgcagtct gacttcagtg ggttcgtgct cctgagggtg agaggagccg tttggtgagt 1920 gcctaccacg tgtcacgtgt gcactacacc ctgtacccac acaatggtca caacaaccct 1980 gggaggtaaa tggaccatgg ccacactaca gatgacaaga ctgtctcaga gaggccctgt 2040 gactaaccca gagcacatgg ccagaaaacg gaggggctgg ctttcaaaac aactgaccga 2100 agctcccagg ctgcccctca catggtcctg aggcctgcag ccctggcgtc cagactgccc 2160 actccccaca aagctcctcc aaacactcta agatggggaa gctctgtctt cccaaaccac 2220 tgcaagctaa accgagccat ccctgcaact gtccactgtc gacattgtgg agcagggaag 2280 cgagtgtggg gtggagggcc gaggtacaaa agatcttaga ggccgcagga agacaaaagc 2340 atgacaagaa ggagcagctg tttgtaaggg aaacttgaga ccggcacaaa gcccagctcc 2400 ctaatcccag gctcctgtgg agccagggcg ggcccccaag gtcagggatc ctaggggcag 2460 gcagatggca gatcggcctc cangcccggg tggggaccca ctcccatgtt cacgaacaac 2520 tgggggccca ttgtcctttc cgggttaagt ccccttcctc tagtgcccca ctctgctctc 2580 ttccctttgg gtttcggggg tcccttccag cttccttctt tctgtgcggg gtccctttta 2640 gtgtgcccta cttcaccccc tccccaattc ctgggagtaa ttttagcaac ttttcctctg 2700 aactgccgct ggcatggtca cagcaaatgg cccctgtttg ggcctgacac tcgatcaggg 2760 tggtgacaga gcccagacaa agcaggcaca gagcccgggg aggggggaca ggagacagat 2820 caccttcctt ccactccagg ccttatttgg tctaccttgg tgaagctgcc ctccctccag 2880 ccccttttat ttatagcctt ttgctctgct ctcctttgtc ttgtcggcta tcactctgca 2940 gtgccctctg cacaaccccc ctcctccccc ctcccctcca tggggccctg gcccctcact 3000 ctccctctag gaatgtgggt gtgtacacag ggcaccagct ccaagctcag gcccgaactc 3060 cacttctctc aactgctgaa tggagcttct cacgggaggg gtctttctct ggtcgctctg 3120 gctagaacaa tgcccagtgc gcagcaggct tccagaagca ctcgctgagt gaggaagtct 3180 gcaggctgct gtccccagat ggcagcaggc agaagcaaga gaagcaccgt ggagccaagg 3240 gcaggtgctg gaggggctgg gacgtcagac cccactgcca ccantaccac cacctaagcc 3300 tggagttagg ggagtgagtt ctattgtgca agagggcttg gagactgaac accaatgctg 3360 atacaccgat gacccagagc cttccagact taaaaggaag cacatgaagc atgatccttt 3420 actaggtgca aaaacagctc ctgcaaaggg ttcaaccgag gctcaagcat cttctgtgtg 3480 tcttcattgc ctgtacctgc tcctgagtcc tgggaactcg gggaaggggg cagccccctt 3540 ctttgcttag gtaaccagaa gggacggacg caagggcttg ctgtccatca ccagtccctg 3600 aggcccctga gtcctcggca cctgcagggc ctggccagga ccctcagcgt ctgcagtcag 3660 ggctttcact ggtgcaggct cagcttcagc agctgcaggc ccacgggtca tggtccaccc 3720 cacccccgcc cgtctgcacc ctgaacacac agtcgcttgt ggttctcaga cctcgccttg 3780 gttaccacgc agcccccaca gaagcccctc ctggagtttc tctccccagc tgtgcccacc 3840 ccaccttcaa catgtacctg atccgcaccc catcccccag gcctgcctct ccttccaagc 3900 tgacagccaa tcagatggat taatccgcac gcgcccaaga gcctcctggg aagaagggga 3960 ggggggtgga tttcaaaacc aaaccacgca gcggttgcct ggacacgaag ccagtcaggc 4020 ttgcctgcaa gagccaggct gtgctctgct cagagcctgc gctccggctc ccgctcctcc 4080 attcccttgc cctgcccgcc tctcagcctc actgtagaac accagtcgca tccaggtctg 4140 ggaagaggtc acaccgctgg aggaacagct gtcctggttc agggtctcct agcttagggc 4200 agctgtgcga tctcccactc ctggggcggg ggtcacctag tagctggggg cgcagaattg 4260 ggaagacaag tcaggcgcgg ggctgactgt gcatcttagt cctgcgctga ctaggaccat 4320 ccagcactgg gccccgagct ctgcacacag tatgtcttcc ctccttccca ggactccctc 4380 cacaggctgc tgctatttcc ccgccctgat tagctgggtg accttaaacc catacttccc 4440 ctctccataa aacgaaaagc ttggacggat aaagacctgt ctggctctgg gactcagtga 4500 tctcaacaca tcgcctgctg atccaaggaa atcagggcct gagccagagg ccccatgtct 4560 tagctccctg gtcatcgtcc gcgcccctta gcgaagcact ctccctccag ctgcccccct 4620 ccagcccctg gttctgccct gccctccctg gagctgagac ttagtccctt ttccatctca 4680 cagttggatg caggctccag gccaggaaag cagggaaatt tcccgttgca gaaacggggc 4740 caggtcagcc ttggaggctg ggggcctaag gggcagcagc atgaggggcc cacagtgccc 4800 tgtgggagag ccagggcctg cctgcctgag gtcacactgg tggtcctggt cagttccctc 4860 tcccacaggc agtggaatgc gaggagatat tttctgctgc acgttgagcc accccgcccc 4920 ctggaactca gaccctgcac accccatgcc ataacaatga cgaccacttc caattgtttc 4980 ctggcccgag ggggagggga gctctctggg agggggggcc ctgggggaaa tgcttccagt 5040 gacaacagcc ctttctaaat ccggctaggg actgggtgca ggtgggggtg ggggcgccct 5100 gctgccccat atatacaacc cctgaggcca ggtctggctc tcagctctct cctgctctgt 5160 gtgtctttcc ttgatgttct caggtaggag cggggagaag ggggctccag gttaggaagg 5220 ggctccccca ggaacagcaa gcttcatcag ggctttgtgc agagtcccag gtccggtcgt 5280 tgagcacacg tgtgcaggtt acacacccgt ggatgtgcca ctgagtgtga cgctcctgta 5340 ttccctgggg aaggtgtctg ggtctgagag tgtgggaacc aaatgaatga gtatgtgtgt 5400 gtgtgtgtgt gtgtgtgtac aagcatgtgc agtcggcagg tgagggaggg gtgtgcctca 5460 ctgtctgacg cagcgagtat tgatgatcgt gcctgagtac gagcagaatc ttttgggagt 5520 gggggggaat ggtgtagaat gattgtacag gaagtgtgga cgcttccaag ctagtcctga 5580 gaaccatctg tccatgcaca tggaggggct tgcctgtgcg tcgggagtca cgaccgctgt 5640 cgtgtgcgtg ccccctgcag aaggcgctcc caggcatgtg ggtgtggggc ttgggtcctt 5700 ctacactaaa gcataggcag ccacatgagc ctgcgtcccc ccacccaggc acataaacat 5760 gcggctccat agggtacctt agggggcggg ttctgtggcc caggaggcgg cctctgtgtg 5820 tgtgagacgt gtgcaagagc aggcatgcat ggtcatgggg gaggtgcagg gtgctcagct 5880 gtgtggtggg tgtgtctaag agaggacacc tgtcgtgtcc acaaagtctg acaatgaatg 5940 ggccagaaaa caactggctt tggagtgggg agagaggggc ttgaggctca gctctaccac 6000 ttaccattta tgctcttgaa taagcaaatc ctgtcacctt ggtttccccg tctgatgcat 6060 gggatgagaa ctgagaggag agtttgtgga ctgcacagca ctgagcaagt gtgaccatta 6120 gctgtgtccc agatagttca aagcaagtct cactagaagg ctatgagcgt ctcccaggag 6180 tgcggaaacc tgttagaact ggtccttggg gcagcaggga acagagctgg gaaaacaaga 6240 tgggagccgg gaagctgact tccagttcca gctgctgttt aggtctgggg gagagcagat 6300 gctgggagac agtcggggga agcgggaggt ggcacgggct aggatgggcc gcagcctgct 6360 ctgacacggc ctcttccctc tccccaggtc ccccgcaggc ctgagtcccc ttcctcatct 6420 gtagacacat ttgagaagcc aaggtaagag aagctgaagg gagagctgca aagactgggc 6480 gtgtgagtcc tgaggccagg ctgtggaacc ctggcttccg tcctgccttg gtggggacat 6540 cctaggtacc aggagcccct cactgtgact agtgagggat gcaggggcag gcaagggtca 6600 gaggtggatg tgagcagact cttgctcctc caagaagctc agagggttct ccccccaacc 6660 cccactccca cccccgcccc cgccttgggg agcctcagcc agaaccagtt agttgctcct 6720 tcctccatgg tgggctcgca aaactgctct tccagtaata ggacaagctc agacaacggg 6780 gacttgctgg ggacacgggt gacccctgaa tgcagagcta ggttttgggg ctcccaccga 6840 agggaagagc tcagggaggg gaaggcagag tggacagatg ggaggaacca gcttcttccg 6900 ctcactacag gtacagaatt caag atg gat gac tcc cag atg gcc gac ttt 6951 Met Asp Asp Ser Gln Met Ala Asp Phe 1 5 ggg gcg gca gcc cag tac ctc cgc aag tcc gag aaa gag cgt cta gag 6999 Gly Ala Ala Ala Gln Tyr Leu Arg Lys Ser Glu Lys Glu Arg Leu Glu 10 15 20 25 gcc cag aca cgg cct ttc gac atc cgc act gag tgc ttt gtg ccc gat 7047 Ala Gln Thr Arg Pro Phe Asp Ile Arg Thr Glu Cys Phe Val Pro Asp 30 35 40 gac aag gag gag ttc gtc aag gcc aag atc gtg tct cgg gag gga ggc 7095 Asp Lys Glu Glu Phe Val Lys Ala Lys Ile Val Ser Arg Glu Gly Gly 45 50 55 aag gtc acc gcc gaa acc gag aac ggc aag acg gtg acc gtg aag gag 7143 Lys Val Thr Ala Glu Thr Glu Asn Gly Lys Thr Val Thr Val Lys Glu 60 65 70 gac cag gtg ttg cag cag aac cca ccc aag ttc gac aag atc gag gac 7191 Asp Gln Val Leu Gln Gln Asn Pro Pro Lys Phe Asp Lys Ile Glu Asp 75 80 85 atg gcc atg ctg acc ttc cta cac gag ccc gct gta ctc tac aac ctc 7239 Met Ala Met Leu Thr Phe Leu His Glu Pro Ala Val Leu Tyr Asn Leu 90 95 100 105 aag gag cgc tac gcg gct tgg atg att tac acc tac tcg ggc ctc ttc 7287 Lys Glu Arg Tyr Ala Ala Trp Met Ile Tyr Thr Tyr Ser Gly Leu Phe 110 115 120 tgc gtc acc gtc aac ccc tac aag tgg ctg ccg gtg tac aat gca gag 7335 Cys Val Thr Val Asn Pro Tyr Lys Trp Leu Pro Val Tyr Asn Ala Glu 125 130 135 gtg gtg gcc gcc tac cgg ggc aag aag agg agc gag gcc ccg ccc cac 7383 Val Val Ala Ala Tyr Arg Gly Lys Lys Arg Ser Glu Ala Pro Pro His 140 145 150 atc ttc tcc atc tct gac aac gcc tat cag tac atg cta aca gat cgg 7431 Ile Phe Ser Ile Ser Asp Asn Ala Tyr Gln Tyr Met Leu Thr Asp Arg 155 160 165 gaa aac cag tcc atc ctc atc acc gga gaa tcc ggg gcg ggg aag aca 7479 Glu Asn Gln Ser Ile Leu Ile Thr Gly Glu Ser Gly Ala Gly Lys Thr 170 175 180 185 gtg aac acc aag cgt gtc atc cag tac ttt gcc agt att gca gcc att 7527 Val Asn Thr Lys Arg Val Ile Gln Tyr Phe Ala Ser Ile Ala Ala Ile 190 195 200 ggt gac cgg ggc aag aag gac aac gtc aat gcc aac aag ggc acc ctg 7575 Gly Asp Arg Gly Lys Lys Asp Asn Val Asn Ala Asn Lys Gly Thr Leu 205 210 215 gag gac cag atc atc cag gcc aac cct gcc ttg gag gcc ttc ggc aac 7623 Glu Asp Gln Ile Ile Gln Ala Asn Pro Ala Leu Glu Ala Phe Gly Asn 220 225 230 gcc aag acc gtc cgg aac gac aac tcc tcg cgc ttc ggg aaa ttc atc 7671 Ala Lys Thr Val Arg Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile 235 240 245 aga atc cac ttt gga gcc act gga aag ctg gct tct gcg gac ata gag 7719 Arg Ile His Phe Gly Ala Thr Gly Lys Leu Ala Ser Ala Asp Ile Glu 250 255 260 265 acc tac ctg ctg gag aag tcc cgg gtg atc ttc cag ctg aag gct gag 7767 Thr Tyr Leu Leu Glu Lys Ser Arg Val Ile Phe Gln Leu Lys Ala Glu 270 275 280 agg aac tac cac atc ttc tac cag atc ctg tcc aac aag aag ccg gag 7815 Arg Asn Tyr His Ile Phe Tyr Gln Ile Leu Ser Asn Lys Lys Pro Glu 285 290 295 ctg ctg gac atg ctg ctg atc aca aac aac ccc tac gac tac gcc ttc 7863 Leu Leu Asp Met Leu Leu Ile Thr Asn Asn Pro Tyr Asp Tyr Ala Phe 300 305 310 gtg tcc cag gga gag gtg tcc gtg gcc tcc atc gac gac tcc gag gag 7911 Val Ser Gln Gly Glu Val Ser Val Ala Ser Ile Asp Asp Ser Glu Glu 315 320 325 ctc atg gcc acc gat aac gcc ttc gac gtg ctg ggc ttc agt tct gag 7959 Leu Met Ala Thr Asp Asn Ala Phe Asp Val Leu Gly Phe Ser Ser Glu 330 335 340 345 gag aaa gtc ggc atc tac aag ctg acg ggc gcc atc atg cac tac gga 8007 Glu Lys Val Gly Ile Tyr Lys Leu Thr Gly Ala Ile Met His Tyr Gly 350 355 360 aac atg aag ttc aag cag aag cag cgt gag gag cag gcg gag ccg gac 8055 Asn Met Lys Phe Lys Gln Lys Gln Arg Glu Glu Gln Ala Glu Pro Asp 365 370 375 ggc acc gaa gat gcc gac aag tcc gcc tac ctc atg ggg ctg aac tcc 8103 Gly Thr Glu Asp Ala Asp Lys Ser Ala Tyr Leu Met Gly Leu Asn Ser 380 385 390 gct gac ctg ctc aag ggg ctg tgc cac cct cgg gtg aaa gtg ggc aac 8151 Ala Asp Leu Leu Lys Gly Leu Cys His Pro Arg Val Lys Val Gly Asn 395 400 405 gag tac gtc acc aag ggg cag aac gtg cag cag gtg tac tac tcc atc 8199 Glu Tyr Val Thr Lys Gly Gln Asn Val Gln Gln Val Tyr Tyr Ser Ile 410 415 420 425 ggg gcg ctg gcc aag gcc gtg tac gag aag atg ttc aac tgg atg gtg 8247 Gly Ala Leu Ala Lys Ala Val Tyr Glu Lys Met Phe Asn Trp Met Val 430 435 440 atg cgc atc aat gcc acg ctg gag acc aag ctg ccg cgc cag tac ttc 8295 Met Arg Ile Asn Ala Thr Leu Glu Thr Lys Leu Pro Arg Gln Tyr Phe 445 450 455 ata ggc gtc ctc gac atc gcg ggc ttc gag atc ttt gac ttc aac agc 8343 Ile Gly Val Leu Asp Ile Ala Gly Phe Glu Ile Phe Asp Phe Asn Ser 460 465 470 ttt gag cag ctt tgc atc aac ttc acc aac gag aag ctg cag cag ttc 8391 Phe Glu Gln Leu Cys Ile Asn Phe Thr Asn Glu Lys Leu Gln Gln Phe 475 480 485 ttc aac cac cac atg ttc gtg ctg gag cag gag gag tac aag aag gag 8439 Phe Asn His His Met Phe Val Leu Glu Gln Glu Glu Tyr Lys Lys Glu 490 495 500 505 ggc atc gag tgg gag ttc atc gac ttc ggc atg gac ctg cag gcc tgc 8487 Gly Ile Glu Trp Glu Phe Ile Asp Phe Gly Met Asp Leu Gln Ala Cys 510 515 520 atc gac ctc att gag aag ccc atg ggc atc atg tcc atc ctg gag gag 8535 Ile Asp Leu Ile Glu Lys Pro Met Gly Ile Met Ser Ile Leu Glu Glu 525 530 535 gag tgc atg ttc ccc aag gcc acc gac atg acc ttc aag gcc aag cta 8583 Glu Cys Met Phe Pro Lys Ala Thr Asp Met Thr Phe Lys Ala Lys Leu 540 545 550 tac gac aac cac ctg ggc aag tcc aac aac ttc cag aag cca cgc aac 8631 Tyr Asp Asn His Leu Gly Lys Ser Asn Asn Phe Gln Lys Pro Arg Asn 555 560 565 gtc aag ggg aag cag gaa gcc cac ttc tcc ctg gtc cac tac gcc ggc 8679 Val Lys Gly Lys Gln Glu Ala His Phe Ser Leu Val His Tyr Ala Gly 570 575 580 585 acc gtg gac tac aac atc ctg ggc tgg ctg gag aag aac aag gac cct 8727 Thr Val Asp Tyr Asn Ile Leu Gly Trp Leu Glu Lys Asn Lys Asp Pro 590 595 600 ctc aac gag acg gtg gtg ggc ctg tac cag aag tcc tcc ctc aag ctg 8775 Leu Asn Glu Thr Val Val Gly Leu Tyr Gln Lys Ser Ser Leu Lys Leu 605 610 615 atg gcc acc ctc ttc gcc acc tat gct tct gcc gac act gcg gac act 8823 Met Ala Thr Leu Phe Ala Thr Tyr Ala Ser Ala Asp Thr Ala Asp Thr 620 625 630 ggc aaa ggc aaa gga ggc aag aaa aag ggc tcg tcc ttc cag aca gtg 8871 Gly Lys Gly Lys Gly Gly Lys Lys Lys Gly Ser Ser Phe Gln Thr Val 635 640 645 tca gct ctc cac cgg gaa aat ctg aac aag ctg atg acc aac ctg agg 8919 Ser Ala Leu His Arg Glu Asn Leu Asn Lys Leu Met Thr Asn Leu Arg 650 655 660 665 acc acc cac cct cac ttc gtg cgc tgc atc atc ccc aat gag cgg aag 8967 Thr Thr His Pro His Phe Val Arg Cys Ile Ile Pro Asn Glu Arg Lys 670 675 680 gct cca ggg gtg atg gac aac ccc ctg gtc atg cac cag ctg cgt tgc 9015 Ala Pro Gly Val Met Asp Asn Pro Leu Val Met His Gln Leu Arg Cys 685 690 695 aac ggc gtg ctg gaa ggc att cgc atc tgc agg aag ggc ttc ccc aac 9063 Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Lys Gly Phe Pro Asn 700 705 710 cgc atc ctc tac ggg gac ttc cgg cag agg tac cgc atc ctg aac cca 9111 Arg Ile Leu Tyr Gly Asp Phe Arg Gln Arg Tyr Arg Ile Leu Asn Pro 715 720 725 gcg gcc atc cct gag ggc cag ttc att gac agc agg aag ggg gcg gag 9159 Ala Ala Ile Pro Glu Gly Gln Phe Ile Asp Ser Arg Lys Gly Ala Glu 730 735 740 745 aag ctg ctg ggc tcc ctg gac att gac cac aac cag tac aag ttc ggc 9207 Lys Leu Leu Gly Ser Leu Asp Ile Asp His Asn Gln Tyr Lys Phe Gly 750 755 760 cac acc aag gtg ttc ttc aag gcc ggg ctg ctg ggg ctg ctg gag gag 9255 His Thr Lys Val Phe Phe Lys Ala Gly Leu Leu Gly Leu Leu Glu Glu 765 770 775 atg cgg gac gag agg ctg agc cgc atc atc acg cgc atc cag gcc cag 9303 Met Arg Asp Glu Arg Leu Ser Arg Ile Ile Thr Arg Ile Gln Ala Gln 780 785 790 tcc cgg ggc cag ctc atg cgt gct gag ttc aag aag atc ctg gag cgc 9351 Ser Arg Gly Gln Leu Met Arg Ala Glu Phe Lys Lys Ile Leu Glu Arg 795 800 805 agg gat gcc ctg ctg gtc atc cag tgg aac atc cgg gcc ttc atg ggg 9399 Arg Asp Ala Leu Leu Val Ile Gln Trp Asn Ile Arg Ala Phe Met Gly 810 815 820 825 gtc aag aac tgg ccc tgg atg aag ctc tac ttc aag atc aag cct ctg 9447 Val Lys Asn Trp Pro Trp Met Lys Leu Tyr Phe Lys Ile Lys Pro Leu 830 835 840 ctg aag agc gcg gag acg gag aag gag atg gcc acc atg aag gag gag 9495 Leu Lys Ser Ala Glu Thr Glu Lys Glu Met Ala Thr Met Lys Glu Glu 845 850 855 ttc ggg cgc atc aaa gag tcc ctg gag aag tcg gag gcc cgc cgc aag 9543 Phe Gly Arg Ile Lys Glu Ser Leu Glu Lys Ser Glu Ala Arg Arg Lys 860 865 870 gag ctg gag gag aag atg gtg tcg ctg ctg cag gag aag aat gac ctg 9591 Glu Leu Glu Glu Lys Met Val Ser Leu Leu Gln Glu Lys Asn Asp Leu 875 880 885 cag ctc caa gtg cag gcg gaa caa gac aac ctc aat gat gcc gag gag 9639 Gln Leu Gln Val Gln Ala Glu Gln Asp Asn Leu Asn Asp Ala Glu Glu 890 895 900 905 cgc tgc gac cag ctg atc aag aac aag atc cag ctg gag gcc aag gtg 9687 Arg Cys Asp Gln Leu Ile Lys Asn Lys Ile Gln Leu Glu Ala Lys Val 910 915 920 aag gag atg aac gag agg ctg gag gac gag gag gag atg aac gcc gag 9735 Lys Glu Met Asn Glu Arg Leu Glu Asp Glu Glu Glu Met Asn Ala Glu 925 930 935 ctc act gcc aag aag cgc aag ctg gaa gac gag tgc tcc gag ctc aag 9783 Leu Thr Ala Lys Lys Arg Lys Leu Glu Asp Glu Cys Ser Glu Leu Lys 940 945 950 aag gac att gac gac ctg gag ctg acg ctg gcc aag gtg gag aag gag 9831 Lys Asp Ile Asp Asp Leu Glu Leu Thr Leu Ala Lys Val Glu Lys Glu 955 960 965 aag cac gca acc gag aac aag gtg aag aac ctg aca gag gag atg gct 9879 Lys His Ala Thr Glu Asn Lys Val Lys Asn Leu Thr Glu Glu Met Ala 970 975 980 985 ggg ctg gac gag atc atc gcc aag ctc acc aag gag aag aaa gct ctg 9927 Gly Leu Asp Glu Ile Ile Ala Lys Leu Thr Lys Glu Lys Lys Ala Leu 990 995 1000 caa gag gcc cac cag cag gcc cta gat gac ctt cag gct gag gag gac 9975 Gln Glu Ala His Gln Gln Ala Leu Asp Asp Leu Gln Ala Glu Glu Asp 1005 1010 1015 aaa gtc aat act ctg acc aag gcc aag ctc aag ctg gag cag cag gtg 10023 Lys Val Asn Thr Leu Thr Lys Ala Lys Leu Lys Leu Glu Gln Gln Val 1020 1025 1030 gac gat ctg gag gga tcc ctg gag cag gag aag aag gtg cgc atg gac 10071 Asp Asp Leu Glu Gly Ser Leu Glu Gln Glu Lys Lys Val Arg Met Asp 1035 1040 1045 ctg gag cga gcc aag cgg aag ctg gag ggt gac ctg aag ctg acc cag 10119 Leu Glu Arg Ala Lys Arg Lys Leu Glu Gly Asp Leu Lys Leu Thr Gln 1050 1055 1060 1065 gag agc atc atg gac ctg gag aat gac aag ctg cag ctg gag gag agg 10167 Glu Ser Ile Met Asp Leu Glu Asn Asp Lys Leu Gln Leu Glu Glu Arg 1070 1075 1080 ctc aag aag aag gag ttt gac atc agt cag ctg aac agc aag atc gag 10215 Leu Lys Lys Lys Glu Phe Asp Ile Ser Gln Leu Asn Ser Lys Ile Glu 1085 1090 1095 gat gag cag gca ctg gcc ctc cag ctg cag aag aag ctg aag gaa aac 10263 Asp Glu Gln Ala Leu Ala Leu Gln Leu Gln Lys Lys Leu Lys Glu Asn 1100 1105 1110 cag gcc cgc atc gag gag ctg gag gag gag ctg gag gcc gag cgc act 10311 Gln Ala Arg Ile Glu Glu Leu Glu Glu Glu Leu Glu Ala Glu Arg Thr 1115 1120 1125 gcc agg gcc aag gtg gag aag ctg cgc tcc gac ctg tcc cgg gag ctg 10359 Ala Arg Ala Lys Val Glu Lys Leu Arg Ser Asp Leu Ser Arg Glu Leu 1130 1135 1140 1145 gag gag atc agc gag cgg ctg gag gag gcc ggc ggg gcc acg tcc gtg 10407 Glu Glu Ile Ser Glu Arg Leu Glu Glu Ala Gly Gly Ala Thr Ser Val 1150 1155 1160 cag att gag atg aac aag aag cgc gag gcc gag ttc cag aag atg cga 10455 Gln Ile Glu Met Asn Lys Lys Arg Glu Ala Glu Phe Gln Lys Met Arg 1165 1170 1175 cgg gac ctg gag gag gcc acg ctg caa cac gag gcc acg gcc gcc gcc 10503 Arg Asp Leu Glu Glu Ala Thr Leu Gln His Glu Ala Thr Ala Ala Ala 1180 1185 1190 ctg cgc aag aag cac gcg gac agc gtg gcc gag ctg ggc gag cag atc 10551 Leu Arg Lys Lys His Ala Asp Ser Val Ala Glu Leu Gly Glu Gln Ile 1195 1200 1205 gac aac ctg cag cgg gtg aag cag aag ctg gaa aag gag aag agc gag 10599 Asp Asn Leu Gln Arg Val Lys Gln Lys Leu Glu Lys Glu Lys Ser Glu 1210 1215 1220 1225 ttc aag ctg gag ctg gat gac gtc acc tcc aac atg gag cag atc atc 10647 Phe Lys Leu Glu Leu Asp Asp Val Thr Ser Asn Met Glu Gln Ile Ile 1230 1235 1240 aag gcc aag gca aac ctg gag aaa gtg tcc cgc acg ctg gaa gac cag 10695 Lys Ala Lys Ala Asn Leu Glu Lys Val Ser Arg Thr Leu Glu Asp Gln 1245 1250 1255 gcc aac gag tac cgc atg aag ctg gag gaa gcc cag cgc tcc ctc aac 10743 Ala Asn Glu Tyr Arg Met Lys Leu Glu Glu Ala Gln Arg Ser Leu Asn 1260 1265 1270 gac ttc acc acc cag cga gcc aag ctg caa acc gag aac gga gag cta 10791 Asp Phe Thr Thr Gln Arg Ala Lys Leu Gln Thr Glu Asn Gly Glu Leu 1275 1280 1285 gcc cgg cag ctg gag gag aag gag gcg ctg atc tcc cag ctg acc cgg 10839 Ala Arg Gln Leu Glu Glu Lys Glu Ala Leu Ile Ser Gln Leu Thr Arg 1290 1295 1300 1305 ggc aag ctg tcc tac acc cag cag atg gag gac ctc aag agg cag ctg 10887 Gly Lys Leu Ser Tyr Thr Gln Gln Met Glu Asp Leu Lys Arg Gln Leu 1310 1315 1320 gag gag gaa ggc aag gcc aag aac gcc ctg gcc cac gcg ctg cag tcg 10935 Glu Glu Glu Gly Lys Ala Lys Asn Ala Leu Ala His Ala Leu Gln Ser 1325 1330 1335 gcc cgc cat gac tgt gac ctg ctg cgg gag cag tac gag gag gag atg 10983 Ala Arg His Asp Cys Asp Leu Leu Arg Glu Gln Tyr Glu Glu Glu Met 1340 1345 1350 gag gcc aag gcg gag ctg cag cgc gtc ctg tcc aag gcc aac tcg gag 11031 Glu Ala Lys Ala Glu Leu Gln Arg Val Leu Ser Lys Ala Asn Ser Glu 1355 1360 1365 gtg gca cag tgg agg acc aaa tat gag acg gac gcc atc cag cgc acc 11079 Val Ala Gln Trp Arg Thr Lys Tyr Glu Thr Asp Ala Ile Gln Arg Thr 1370 1375 1380 1385 gag gag ctg gag gag gcc aag aag aag ctg gcc cag cgg ctg cag gac 11127 Glu Glu Leu Glu Glu Ala Lys Lys Lys Leu Ala Gln Arg Leu Gln Asp 1390 1395 1400 gcc gag gag gcc gtg gag gcc gtc aac gcc aag tgc tcc tca ctg gag 11175 Ala Glu Glu Ala Val Glu Ala Val Asn Ala Lys Cys Ser Ser Leu Glu 1405 1410 1415 aag acc aag cac cgg ctg cag aac gag atc gag gac ctc atg gtg gac 11223 Lys Thr Lys His Arg Leu Gln Asn Glu Ile Glu Asp Leu Met Val Asp 1420 1425 1430 gtg gag cgc tcc aac gct gcc gcc gcc gcc ctg gac aag aag cag agg 11271 Val Glu Arg Ser Asn Ala Ala Ala Ala Ala Leu Asp Lys Lys Gln Arg 1435 1440 1445 aac ttc gac aag atc ctg gcc gag tgg aag cag aag tac gag gag tcg 11319 Asn Phe Asp Lys Ile Leu Ala Glu Trp Lys Gln Lys Tyr Glu Glu Ser 1450 1455 1460 1465 cag tcg gag ctg gag tcc tcg cag aag gag gcg cgc tcc ctc agc acc 11367 Gln Ser Glu Leu Glu Ser Ser Gln Lys Glu Ala Arg Ser Leu Ser Thr 1470 1475 1480 gag ctc ttc aag ctc aag aac gcc tac gag gag tcc ctg gag cac ctg 11415 Glu Leu Phe Lys Leu Lys Asn Ala Tyr Glu Glu Ser Leu Glu His Leu 1485 1490 1495 gag acc ttc aag cgg gag aac aag aac ctg cag gag gag atc tct gac 11463 Glu Thr Phe Lys Arg Glu Asn Lys Asn Leu Gln Glu Glu Ile Ser Asp 1500 1505 1510 ctg acg gag cag ctg gga gaa gga ggc aag aat ctg cac gag ctg gag 11511 Leu Thr Glu Gln Leu Gly Glu Gly Gly Lys Asn Leu His Glu Leu Glu 1515 1520 1525 aag gtc cgc aag cag ctg gag gcc gag aag ctg gag ctg cag tcg gcc 11559 Lys Val Arg Lys Gln Leu Glu Ala Glu Lys Leu Glu Leu Gln Ser Ala 1530 1535 1540 1545 ctg gag gag gcc gag gcc tcc ctg gag cac gag gaa ggc aag atc ctc 11607 Leu Glu Glu Ala Glu Ala Ser Leu Glu His Glu Glu Gly Lys Ile Leu 1550 1555 1560 cgg gcc cag ctg gag ttc aac cag atc aag gcg gag atc gag cgg aag 11655 Arg Ala Gln Leu Glu Phe Asn Gln Ile Lys Ala Glu Ile Glu Arg Lys 1565 1570 1575 ctg gtg gag aag gac gag gag atg gaa cag gcc aag cgc aac cac ctg 11703 Leu Val Glu Lys Asp Glu Glu Met Glu Gln Ala Lys Arg Asn His Leu 1580 1585 1590 cgg gtg gtg gac tca ctg cag acc tcc ctg gat gca gag acg cgc agc 11751 Arg Val Val Asp Ser Leu Gln Thr Ser Leu Asp Ala Glu Thr Arg Ser 1595 1600 1605 cgc aac gag gcc ctg cgg gtg aag aag aag atg gag ggc gac ctc aac 11799 Arg Asn Glu Ala Leu Arg Val Lys Lys Lys Met Glu Gly Asp Leu Asn 1610 1615 1620 1625 gag atg gag atc cag ctc agc cag gcc aac agg acg gcc tcc gag gcc 11847 Glu Met Glu Ile Gln Leu Ser Gln Ala Asn Arg Thr Ala Ser Glu Ala 1630 1635 1640 cag aag cac ctg aag aac gcc caa gcc cac ctg aag gac acc cag atc 11895 Gln Lys His Leu Lys Asn Ala Gln Ala His Leu Lys Asp Thr Gln Ile 1645 1650 1655 cag ctg gat gac gcg gtc cgg gcc aat gac gac ctg aag gag aac atc 11943 Gln Leu Asp Asp Ala Val Arg Ala Asn Asp Asp Leu Lys Glu Asn Ile 1660 1665 1670 gcc atc gtg gag cgg cgc aac gcg ctg ctg cag gcc gag ctg gag gag 11991 Ala Ile Val Glu Arg Arg Asn Ala Leu Leu Gln Ala Glu Leu Glu Glu 1675 1680 1685 ctg cgg gcc gtg gtg gag cag acg gag cgg tct cgg aag ctg gca gag 12039 Leu Arg Ala Val Val Glu Gln Thr Glu Arg Ser Arg Lys Leu Ala Glu 1690 1695 1700 1705 cag gag ctg atc gag acc agc gag cgg gtg cag ctg ctg cac tcc cag 12087 Gln Glu Leu Ile Glu Thr Ser Glu Arg Val Gln Leu Leu His Ser Gln 1710 1715 1720 aac acc agc ctc atc aac cag aag aag aag atg gag tcg gac ctg acc 12135 Asn Thr Ser Leu Ile Asn Gln Lys Lys Lys Met Glu Ser Asp Leu Thr 1725 1730 1735 cag ctg cag acg gaa gtg gag gag gcg gtg cag gaa tgc agg aac gcc 12183 Gln Leu Gln Thr Glu Val Glu Glu Ala Val Gln Glu Cys Arg Asn Ala 1740 1745 1750 gag gag aag gcc aag aag gcc atc acg gac gcc gcc atg atg gcg gag 12231 Glu Glu Lys Ala Lys Lys Ala Ile Thr Asp Ala Ala Met Met Ala Glu 1755 1760 1765 gag ctg aag aag gag cag gac acc agc gcc cac ctg gag cgc atg aag 12279 Glu Leu Lys Lys Glu Gln Asp Thr Ser Ala His Leu Glu Arg Met Lys 1770 1775 1780 1785 aag aac atg gag cag acc att aag gac ctg cag cac cgg ctg gac gag 12327 Lys Asn Met Glu Gln Thr Ile Lys Asp Leu Gln His Arg Leu Asp Glu 1790 1795 1800 gcc gag cag atc gcc ctc aag ggc ggc aag aag cag ctg cag aag ctg 12375 Ala Glu Gln Ile Ala Leu Lys Gly Gly Lys Lys Gln Leu Gln Lys Leu 1805 1810 1815 gag gcg cgg gtg cgg gag ctg gag aat gag ctg gag gcc gag cag aag 12423 Glu Ala Arg Val Arg Glu Leu Glu Asn Glu Leu Glu Ala Glu Gln Lys 1820 1825 1830 cgc aac gcg gag tcg gtg aag ggc atg agg aag agc gag cgg cgc atc 12471 Arg Asn Ala Glu Ser Val Lys Gly Met Arg Lys Ser Glu Arg Arg Ile 1835 1840 1845 aag gag ctc acc tac cag acg gag gag gac aag aag aac ctg ctg cgg 12519 Lys Glu Leu Thr Tyr Gln Thr Glu Glu Asp Lys Lys Asn Leu Leu Arg 1850 1855 1860 1865 ctg cag gac ctg gtg gac aag ctg cag ctg aag gtc aag gcc tac aag 12567 Leu Gln Asp Leu Val Asp Lys Leu Gln Leu Lys Val Lys Ala Tyr Lys 1870 1875 1880 cgc cag gcc gag gag gcg gag gag cag gcc aac acc aac ctg tcc aag 12615 Arg Gln Ala Glu Glu Ala Glu Glu Gln Ala Asn Thr Asn Leu Ser Lys 1885 1890 1895 ttc cgc aag gtg cag cac gag ctg gac gag gcg gag gag cgg gca gac 12663 Phe Arg Lys Val Gln His Glu Leu Asp Glu Ala Glu Glu Arg Ala Asp 1900 1905 1910 atc gcg gag tcc cag gtc aac aag ctg cgg gcc aag agc cgc gac atc 12711 Ile Ala Glu Ser Gln Val Asn Lys Leu Arg Ala Lys Ser Arg Asp Ile 1915 1920 1925 ggc gcc aag caa aaa atg cac gac gag gag tga cgccgcctcc ggaaccccgc 12764 Gly Ala Lys Gln Lys Met His Asp Glu Glu * 1930 1935 tcttgttaac ccgcaataaa cacgagtgcc tgaattc 12801 

That which is claimed:
 1. An animal cell stably transformed with an expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID No:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 2. The animal cell of claim 1, wherein said animal cell is from a mammal.
 3. The animal cell of claim 2, wherein said animal cell is selected from the group consisting of rabbit, mouse, monkey, dog, pig, goat, and cow.
 4. The animal cell of claim 1, wherein said animal cell is from cardiac tissue.
 5. The animal cell of claim 4, wherein said animal cell is selected from the group consisting of ventricular and atrial tissue.
 6. The animal cell of claim 1, wherein said promoter is capable of initiating tissue-preferred transcription.
 7. The animal cell of claim 1, wherein said tissue-preferred transcription is cardiac-preferred transcription.
 8. The animal cell of claim 7, wherein said cardiac-preferred transcription is ventricle-preferred transcription.
 9. The animal cell of claim 7, wherein said cardiac-preferred transcription is atria-preferred transcription.
 10. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 11. The rabbit of claim 10, wherein said promoter is capable of initiating tissue-preferred transcription.
 12. The rabbit of claim 11, wherein said tissue-preferred transcription is cardiac-preferred transcription.
 13. The rabbit of claim 12, wherein said cardiac-preferred transcription is ventricle-preferred transcription.
 14. The rabbit of claim 12, wherein said cardiac-preferred transcription is atria-preferred transcription.
 15. The rabbit of claim 10, wherein said rabbit exhibits altered expression of the heterologous nucleotide sequence.
 16. The rabbit of claim 10, wherein said expression is cardiac-preferred expression.
 17. The rabbit of claim 10, wherein said heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of: a.) a nucleotide sequence set forth in SEQ ID NO:3; b.) a nucleotide sequence having at least 95% identity to the nucleotide sequence set forth in SEQ ID NO:3; c.) a nucleotide sequence encoding a polypeptide having the amino acid sequence set forth in SEQ ID NO:4; and d.) a nucleotide sequence encoding a polypeptide having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:4.
 18. The rabbit of claim 17, wherein said promoter is capable of initiating ventricle-preferred transcription and said rabbit exhibits altered myosin isoform expression.
 19. A transgenic animal comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 20. The animal of claim 19, wherein said promoter is capable of initiating tissue-preferred transcription.
 21. The animal of claim 20, wherein said tissue-preferred transcription is cardiac-preferred transcription.
 22. The animal of claim 21, wherein said cardiac-preferred transcription is ventricle-preferred transcription.
 23. The animal of claim 21, wherein said cardiac-preferred transcription is atria-preferred transcription.
 24. The animal of claim 19, wherein said animal exhibits altered expression of the heterologous nucleotide sequence.
 25. The animal of claim 19, wherein said expression is cardiac-preferred expression.
 26. The animal of claim 19, wherein said animal is selected from the group consisting of rabbit, mouse, dog, pig, goat, cow, monkey, chimpanzee, and sheep.
 27. A method of altering expression of a heterologous nucleotide sequence in an animal, said method comprising: a.) providing a transgenic animal comprising in its genome at least one stably incorporated expression cassette comprising: i.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: a.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; b.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in a cell of said animal; and c.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in a cell of said animal; and ii.) a heterologous nucleotide sequence operably linked to said promoter; and b.) determining expression levels of said heterologous nucleotide sequence in said animal.
 28. The method of claim 27, wherein said expression is cardiac-preferred expression.
 29. The method of claim 27, wherein said animal is selected from the group consisting of rabbit, mouse, dog, pig, goat, cow, chimpanzee, and sheep.
 30. The method of claim 27, wherein said expression occurs in cardiac tissue.
 31. The method of claim 30, wherein said cardiac tissue is selected from the group consisting of ventricle tissue and atria tissue.
 32. The method of claim 27, wherein said expression alters the animal's susceptibility to cardiopathy.
 33. The method of claim 32, wherein said cardiopathy is a cardiomyopathy.
 34. A method of identifying anti-cardiopathic compounds, comprising the steps of: a.) providing a first and second transgenic rabbit whose genomes comprise an expression cassette comprising: i.) a promoter capable of initiating cardiac-preferred transcription, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: a.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; b.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating cardiac-preferred transcription; and c.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating cardiac-preferred transcription; and ii.) a heterologous nucleotide sequence operably linked to said promoter; b.) administering a compound to said first rabbit; c.) incubating both the first and second rabbits for a period of time; and d.) monitoring said first rabbit for a modulation of a cardiopathic phenotype in said first rabbit compared to said second rabbit.
 35. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises the nucleotide sequence set forth in SEQ ID NO:1; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 36. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence having at least 90% identity to the nucleotide sequence set forth in SEQ ID NO:1, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 37. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises the nucleotide sequence set forth in SEQ ID NO:2; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 38. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence having at least 90% identity to the nucleotide sequence set forth in SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 39. A transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising the nucleotide sequence set forth in SEQ ID NO:5.
 40. A kit comprising a transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 41. A kit comprising a transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising the nucleotide sequence set forth in SEQ ID NO:5.
 42. A kit for performing a method of altering expression of a heterologous nucleotide sequence in a rabbit, said kit comprising a transgenic rabbit comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 43. A kit for performing a method of altering expression of a heterologous nucleotide sequence in an animal, said kit comprising at least one expression cassette comprising a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: a.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; b.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and c.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell.
 44. A kit for altering an animal's susceptibility to a cardiopathy, said kit comprising a transgenic animal comprising in its genome at least one stably incorporated expression cassette comprising: a.) a promoter, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating transcription in an animal cell; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 45. The kit of claim 44, further comprising a non-transgenic animal.
 46. The kit of claim 44, wherein said animal is a rabbit.
 47. The kit of claim 44, further comprising a non-transgenic rabbit.
 48. A kit for identifying anti-cardiopathic compounds, said kit comprising a first transgenic rabbit and a second transgenic rabbit whose genomes comprise an expression cassette comprising: a.) a promoter capable of initiating cardiac-preferred transcription, wherein said promoter comprises a nucleotide sequence selected from the group consisting of: i.) a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2; ii.) a nucleotide sequence having at least 90% identity to a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating cardiac-preferred transcription; and iii.) a nucleotide sequence comprising at least 50 contiguous nucleotides of a nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, wherein said nucleotide sequence is capable of initiating cardiac-preferred transcription; and b.) a heterologous nucleotide sequence operably linked to said promoter.
 49. The kit of claim 48, wherein the genomes of said transgenic rabbits comprise at least one stably incorporated expression cassette comprising the nucleotide sequence set forth in SEQ ID NO:5. 